WO1997043238A9 - Substituted oxobutyric acids as matrix metalloprotease inhibitors - Google Patents
Substituted oxobutyric acids as matrix metalloprotease inhibitorsInfo
- Publication number
- WO1997043238A9 WO1997043238A9 PCT/US1997/007975 US9707975W WO9743238A9 WO 1997043238 A9 WO1997043238 A9 WO 1997043238A9 US 9707975 W US9707975 W US 9707975W WO 9743238 A9 WO9743238 A9 WO 9743238A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbons
- mmp
- compounds
- alkyl
- matnx
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title abstract description 4
- 239000002253 acid Substances 0.000 title description 25
- 150000007513 acids Chemical class 0.000 title description 7
- 239000003475 metalloproteinase inhibitor Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 78
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 51
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 36
- 230000000694 effects Effects 0.000 claims abstract description 28
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 25
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 25
- 102000005741 Metalloproteases Human genes 0.000 claims abstract description 21
- 108010006035 Metalloproteases Proteins 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 210000000845 Cartilage Anatomy 0.000 claims abstract description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 7
- 230000001404 mediated Effects 0.000 claims abstract description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 6
- 150000004820 halides Chemical class 0.000 claims abstract description 6
- 206010027476 Metastasis Diseases 0.000 claims abstract description 5
- 208000009400 Aortic Disease Diseases 0.000 claims abstract description 4
- 208000002528 Coronary Thrombosis Diseases 0.000 claims abstract description 4
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims abstract description 4
- 208000009883 Joint Disease Diseases 0.000 claims abstract description 4
- 206010060820 Joint injury Diseases 0.000 claims abstract description 4
- 230000003412 degenerative Effects 0.000 claims abstract description 4
- 230000028709 inflammatory response Effects 0.000 claims abstract description 4
- 210000000653 nervous system Anatomy 0.000 claims abstract description 4
- 230000000472 traumatic Effects 0.000 claims abstract description 4
- 206010053177 Epidermolysis Diseases 0.000 claims abstract description 3
- 206010049088 Osteopenia Diseases 0.000 claims abstract description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims abstract description 3
- 201000001474 proteinuria Diseases 0.000 claims abstract description 3
- 201000008482 osteoarthritis Diseases 0.000 claims abstract 3
- 206010053555 Arthritis bacterial Diseases 0.000 claims abstract 2
- 201000008838 periodontal disease Diseases 0.000 claims abstract 2
- 201000001223 septic arthritis Diseases 0.000 claims abstract 2
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000036269 ulceration Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract description 4
- 230000003143 atherosclerotic Effects 0.000 abstract description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 27
- 239000003112 inhibitor Substances 0.000 description 26
- 125000001424 substituent group Chemical group 0.000 description 23
- 125000003118 aryl group Chemical group 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 22
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- 229940088598 Enzyme Drugs 0.000 description 18
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drugs Drugs 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 125000005842 heteroatoms Chemical group 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 101700040359 MMP3 Proteins 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 102100014894 MMP2 Human genes 0.000 description 12
- 101700060512 MMP2 Proteins 0.000 description 12
- 102100014893 MMP3 Human genes 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 238000004166 bioassay Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 125000004429 atoms Chemical group 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 102100006844 MMP9 Human genes 0.000 description 7
- 101700067851 MMP9 Proteins 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000002194 synthesizing Effects 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 239000008079 hexane Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000003003 spiro group Chemical group 0.000 description 6
- -1 acids compounds Chemical class 0.000 description 5
- 125000004432 carbon atoms Chemical group C* 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000001072 Colon Anatomy 0.000 description 4
- 238000006751 Mitsunobu reaction Methods 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- RXSUFCOOZSGWSW-UHFFFAOYSA-M acetyloxy-(4-aminophenyl)mercury Chemical compound CC(=O)O[Hg]C1=CC=C(N)C=C1 RXSUFCOOZSGWSW-UHFFFAOYSA-M 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 150000002690 malonic acid derivatives Chemical class 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 108010067415 progelatinase Proteins 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical group [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 4
- 230000002797 proteolythic Effects 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 230000036499 Half live Effects 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 3
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 3
- 210000004379 Membranes Anatomy 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 108091005771 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CVNRXYGLZPPQHP-UHFFFAOYSA-N 1-bromotetradecan-2-one Chemical compound CCCCCCCCCCCCC(=O)CBr CVNRXYGLZPPQHP-UHFFFAOYSA-N 0.000 description 2
- LSKONYYRONEBKA-UHFFFAOYSA-N 2-Dodecanone Chemical compound CCCCCCCCCCC(C)=O LSKONYYRONEBKA-UHFFFAOYSA-N 0.000 description 2
- 210000001188 Cartilage, Articular Anatomy 0.000 description 2
- 210000004087 Cornea Anatomy 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N Cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N Diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 2
- 102100018200 MMP1 Human genes 0.000 description 2
- 101700019781 MMP1 Proteins 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 2
- 102000001776 Matrix Metalloproteinase 9 Human genes 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- VUVGYHUDAICLFK-UHFFFAOYSA-N Perosmic oxide Chemical compound O=[Os](=O)(=O)=O VUVGYHUDAICLFK-UHFFFAOYSA-N 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001066 destructive Effects 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- PPJTVWKLYZPWAI-UHFFFAOYSA-N ethenoxysilicon Chemical compound [Si]OC=C PPJTVWKLYZPWAI-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940020899 hematological Enzymes Drugs 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 101700070750 inh Proteins 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 200000000023 metastatic cancer Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000003204 osmotic Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- MXXVXUKTFUBSKJ-RSAXXLAASA-N 1,3-dichloropropan-2-one;(2S)-2-[(4-methylphenyl)sulfonylamino]-3-phenylpropanoic acid Chemical compound ClCC(=O)CCl.C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MXXVXUKTFUBSKJ-RSAXXLAASA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-Phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- LZWKGSAOQVIURA-UHFFFAOYSA-N 2-[2-(1,3-dioxoisoindol-2-yl)ethyl]-4-oxopentadecanoic acid Chemical compound C1=CC=C2C(=O)N(CCC(CC(=O)CCCCCCCCCCC)C(O)=O)C(=O)C2=C1 LZWKGSAOQVIURA-UHFFFAOYSA-N 0.000 description 1
- 101710006356 ACTI Proteins 0.000 description 1
- FXXACINHVKSMDR-UHFFFAOYSA-N Acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N Aminomethylphosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 210000002469 Basement Membrane Anatomy 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N Batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 Batimastat Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N Benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100009062 C3orf52 Human genes 0.000 description 1
- 101710043960 C3orf52 Proteins 0.000 description 1
- 101700046715 CSTI Proteins 0.000 description 1
- MOIPGXQKZSZOQX-UHFFFAOYSA-N Carbonyl bromide Chemical class BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
- 210000001612 Chondrocytes Anatomy 0.000 description 1
- 241001439061 Cocksfoot streak virus Species 0.000 description 1
- 108060005980 Collagenase family Proteins 0.000 description 1
- 102000020504 Collagenase family Human genes 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101700020566 DEFA4 Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GQZXNSPRSGFJLY-UHFFFAOYSA-N Hypophosphorous acid Chemical compound OP=O GQZXNSPRSGFJLY-UHFFFAOYSA-N 0.000 description 1
- 101700072148 IAA2 Proteins 0.000 description 1
- 101710006353 IP3R Proteins 0.000 description 1
- 101700035656 ISOTI Proteins 0.000 description 1
- 101700035039 ITI Proteins 0.000 description 1
- 101700052013 ITR2 Proteins 0.000 description 1
- 101700068039 ITRP Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 101700036939 MTI Proteins 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 108010015302 Matrix Metalloproteinase 9 Proteins 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N N-benzyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 102100002509 NQO1 Human genes 0.000 description 1
- 229910020936 NaC Inorganic materials 0.000 description 1
- 101700057326 Oacyl Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 101710005767 POLR3C Proteins 0.000 description 1
- 102000016387 Pancreatic Elastase Human genes 0.000 description 1
- 108010067372 Pancreatic Elastase Proteins 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 229950005134 Polycarbophil Drugs 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M Potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960004793 Sucrose Drugs 0.000 description 1
- 101700062451 TI Proteins 0.000 description 1
- 101700075175 Timp Proteins 0.000 description 1
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 208000007089 Vaccinia Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 108010066657 azoreductase Proteins 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 229940079919 digestives Enzyme preparations Drugs 0.000 description 1
- DRXGWTUAIWQOKN-UHFFFAOYSA-L dihydroxy(dioxo)molybdenum;phosphonic acid Chemical compound OP(O)=O.O[Mo](O)(=O)=O DRXGWTUAIWQOKN-UHFFFAOYSA-L 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 101700063725 hap2 Proteins 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitors Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical group CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000000541 pulsatile Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 108091007018 stromelysin Proteins 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 150000008648 triflates Chemical group 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Definitions
- This invention relates to enzyme inhibitors, and more particularly, to novel oxobury ⁇ c acids compounds or derivatives thereof useful for inhibiting matnx metalloproteases.
- the matnx metalloproteases (a.k.a. matnx metalloendo-protemases or MMPs i are a famrn of zinc endoproteinases which include, but are not limned to. interstitial collagena ⁇ e (a.k.a.
- MMP- 1 stromelysin (a.k.a.. proteoglycanase. transin. or MMP-3), gelatinase A (a.k.a.. 72kDa-geiaunase or MMP-2) and gelatinase B (a.k.a.. 95kDa-gelat ⁇ nase or MMP-9).
- MMPs are secreted by a variety of cells including fibroblasts and chondrocytes. along with natural proteinaceous inhibitors known as TTMPs (Tissue Inhibitor of MetalloProteinase). All of these MMPs are capable of destroying a vanery of connective tissue components of articular cartilage or basement membranes.
- MMP-3 Each MMP is secreted as an inactive proenzyme which must be cleaved in a subsequent step before it is able to exert its own proteolytic activity
- MMP-3 certain of these MMPs such as MMP-3 have been implemented as the in vivo activator for other MMPs such as MMP-1 and MMP-9 (Ito. et al.. Arch Biochem Biophys. 67, 21 1 ( 1988); Ogata, et al.. J. Biol. Chem., 267, 3581 (1992)).
- MMP-1 and MMP-9 Ito. et al.. Arch Biochem Biophys. 67, 21 1 ( 1988); Ogata, et al.. J. Biol. Chem., 267, 3581 (1992)
- MMP-3 inhibitors should limit the activity of other MMPs that are not directly inhibited by such inhibitors. It has also been reported that MMP-3 can cleave and thereby inactivate the endogenous inhibitors of other protemases such as elastase (Wmyard. et al .
- Inhibitors of MMP-3 could thus influence the activity of other destructive protemases by modifying the level of their endogenous inhibitors
- a number of diseases are thought to be mediated by excess or undesired mat ⁇ x-destroying metalloprotease activity or by an imbalance in the ratio of the MMPs to the TIMPs
- These include a) osteoarth ⁇ us (Woessner, et al , J. Biol Chem , 259(6). 3633 (1984), Phadke. et al . J Rheumatol 10, 852 (1983)), b) rheumatoid arth ⁇ tis (Mullins, et al..
- OA osteoarth ⁇ tis
- RA rheumatoid arth ⁇ tis
- septic arth ⁇ tis is the progressive loss of articular cartilage and thereby normal joint function.
- No marketed pharmaceutical agent is able to prevent or slow this cartilage loss, although nonsteroidal anti- inflammatory drugs (NS AIDs) have been given to control pain and swelling.
- N AIDs nonsteroidal anti- inflammatory drugs
- the end result of these diseases is total loss of joint function which is only treatable by joint replacement surgery.
- MMP inhibitors are expected to halt or reverse the progression of cartilage loss and obviate or dela> surgical intervention.
- Proteases are c ⁇ tical elements at several stages in the progression of metastatic cancer.
- the proteolytic degradation of structural protem in the basal membrane allows for expansion of a tumor in the p ⁇ mary site, evasion from this site as well as homing and invasion in distant, secondary sues.
- tumor induced angiogenesis is required for tumor growth and is dependent on proteolytic tissue remodeling
- Transfection experiments with vanous types of proteases have shown that the matnx metalloproteases play a dominant role in these processes in particular gelaunases A and B (MMP-2 and MMP-9, respectively).
- MMP-2 and MMP-9 gelaunases
- N-carboxyalkyl derivatives containing a biphenylethylglycine are inhibitors of stromelysin- 1 (MMP-3).
- MMP-2 72 kDA gelatinase
- collagenase Disette, et al., WO-9529689.
- MMP inhibitors which possess improved bioavailabihty and biological stability relative to the peptide-based compounds of the prior art, and which can be optimized for use against particular target MMPs. Such compounds are the subject of the present application.
- MMP inhibitors would afford new therapies for diseases mediated by the presence of. or an excess of MMP activity, including osteoarth ⁇ tis. rheumatoid arthritis, sepuc arthritis, tumor metastasis, pe ⁇ odontal diseases, cornea! uicerations. and proteinuria.
- MMP activity including osteoarth ⁇ tis. rheumatoid arthritis, sepuc arthritis, tumor metastasis, pe ⁇ odontal diseases, cornea! uicerations. and proteinuria.
- thiols Beszant. et al.
- This invention provides compounds having matnx metal loprotease inhibitory activity These compounds are useful for inhibiting matnx metalloproteases and, therefore, combating conditions to which MMPs contribute Accordingly, the present invention also provides pharmaceutical compositions and methods for treating such conditions
- the compounds desc ⁇ bed relate to a method of treating a mammal compnsmg admiruste ⁇ ng to the mammal a matnx metalloprotease inhibiting amount of a compound according to the invention sufficient to
- the present compounds can be used to modulate MMP action, thereby allowing the researcher to observe the effects of reduced MMP activity in the expe ⁇ mental biological system under study
- This invention relates to compounds having matnx metal loprotease inhibitory activity and the generalized formula
- A-D-E-G (L) A represents alkyl. allyl-, benzyioxy-, or 3-propynyl alkyl groups as well as the structure
- R' 7 is -C : H ⁇ . -allyl. or -benzyl.
- D represents
- E represents a chain of n carbon atoms beanng m substituents R 6 in which the R 6 groups are independent substituents. or constitute spiro or nonspiro nngs. Rings may be formed in two ways: a) two groups R 6 are joined, and taken together with the chain atom(s) to which the two R ⁇ group(s) are attached, and any intervening chain atoms, constitute a 3 - 7 embered ⁇ ng, or b) one group R 6 is joined to the chain on which this one group R 6 resides, and taken together with the chain atom(s) to which the R 6 group is attached, and any intervening chain atoms, constitutes a 3 - 7 membered ring.
- the number n of carbon atoms in the chain is 2 or 3, and the number m of R 6 substituents is an integer of 1 - 3.
- the number of carbons in the totality of R 6 groups is at least two.
- Each group R* is alkyl. alkenyl. alkynyl, aryl, heteroaryl. non-aromatic cyclic, and combmauons thereof optionally substituted with one or more hetero-atoms as described more fully below
- E is a substituted mono- or bicyclic moiety optionally substituted with one or more heteroatoms.
- G represents -CO H, -PO 3 H ; , -M,
- R" may be H, Cl, MeO or
- the compounds of the present invention are mate ⁇ als having matnx metalloprotease inhibitory activity and the generalized formula:
- A is also represented by the structure:
- R l 5 may be -H. -Cl. -OMe or
- n is 0-4, R 17 is C,H 5 . allyl, or benzyl.
- D represents the moieties
- an open bond indicates the point at which the structure joins to another group.
- E represents a chain of n carbon atoms bea ⁇ ng m substituents R 6 .
- R 6 groups or R 6 units The R 6 groups are independent substituents, or constitute spiro or nonspiro ⁇ ngs. Rings may be formed in two ways: a) two groups R ⁇ are joined, and taken together with the cham atom(s) to which the two R 6 group(s) are attached, and any intervening chain atoms, constitute a 3 - 7 membered ⁇ ng.
- one group R 6 is joined to the chain on which this one group R 6 resides, and taken together with the chain atom(s) to which the R 6 group is attached, and any intervening chain atoms, constitutes a 3 - 7 membered ⁇ ng.
- the number n of carbon atoms in the chain is 2 or 3, and the number m of R 6 substituents is an integer of 1 - 3.
- the number of carbons in the totality of R* groups is at least two.
- Each group R 6 is independently selected from the group consisting of the substituents listed below as items 1) - 14): 1) alkyl of 1 - 10 carbons;
- arylalkyl in which the aryl portion contains 6 - 10 carbons and d e alkyl portion contains 1 - 8 carbons; 5) heteroaryl-alkyl in which the heteroaryl portion comp ⁇ ses 4 - 9 carbons and at least one N, O, or S heteroatom. and the alkyl portion contains 1 - 8 carbons;
- aryl-alkenyl in which the aryl portion contains 6 - 10 carbons and the alkenyi portion contains 2 - 5 carbons;
- heteroaryl-alkenyl in which the heteroaryl portion comp ⁇ ses 4 - 9 carbons and at least one N, O. or S heteroatom and the alkenyi portion contains 2 -5 carbons.
- aryl-alkynyl in which the aryl portion contains 6 - 10 carbons and the alkynyl portion contains 2 - 5 carbons.
- heteroaryl -alkynyl in which the heteroaryl portion comp ⁇ ses 4 - 9 carbons and at least one N. O, or S heteroatom and the alkynyl portion contains 2 - 5 carbons;
- R 1 represents H or alkyl of 1 - 3 carbons
- R : represents H, alkyl of 1 - 6 carbons, aryl of 6 - 10 carbons, heteroaryl comp ⁇ sing 4 - 9 carbons and at least one N. O, or S heteroatom.
- arylalkyi in which the aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 4 carbons, or heteroaryl-alkyl in which the heteroaryl portion comp ⁇ ses 4 - 9 carbons and at least one N, O, or
- R 5 represents alkyl of 1 - 4 carbons, aryl of 6 - 10 carbons, heteroaryl comp ⁇ sing 4 - 9 carbons and at least one N, O, or S heteroatom, arylalkyi in which the aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 4 carbons, or heteroaryl-alkyl in which the heteroaryl portion compnses 4 - 9 carbons and at least one N, O, or S heteroatom and the alkyl portion contains
- heteroaryl comp ⁇ sing 4 to 9 carbons and at least one N, O, or S heteroatom arylalkyi in which the aryl portion contains 6 to 12 carbons and the alkyl portion contains 1 to 4 carbons; heteroaiylalkyl in which the aryl portion contains 6 to 12 carbons and at least one N, O, or S heteroatom and the alkyl portion contains 1 to 4 carbons, -C(O)R 9 in which the R' represents alkyl of 2 to 6 carbons, aryl of 6 to 10 carbons, heteroaryl comp ⁇ sing 4 to
- R 5 are as defined above; and when the A un t is phenyl, the B unit is phenylene. m is 1. n is 2. and v is 0, then x is 1 or 2.
- aryl or heteroaryl portions of any of the R 6 groups optionally may bear up to two substituents selected from the group consisting of -(CH 2 ⁇ C(R")(R' 2 )OH, -(CH 2 ),OR". -( CH 2 ⁇ SR”.
- G represents -CO 2 H. -PO,H 2 , -M,
- alkyl means straight, branched, cyclic. and polycyclic materials.
- haloaikyl means partially or fully halogenated alkyl groups such as -(CH ; ) 2 C1. -CF 3 and -C 6 F 13 for example.
- the invention relates to compounds of generalized formula CL). wherein n is 2 and m is 1 in the E unit. These compounds thus possess two carbon atoms between the D unit and the G unit, and carry one substituent on this two-carbon chain.
- the invention relates to compounds of generalized formula CL) in which the number of substituents m on the E unit is 2 or 3; and when m is 2, both groups R 6 are independent substituents, or together constitute a spiro ⁇ ng. or one group R* is an independent substituent and the other constitutes a spiro ⁇ ng; and when m is 3.
- rwo groups R 6 are independent substituents and one group R 6 constitutes a ⁇ ng, or two groups R 'constitute a ring and one group R6 is an independent substituent. or three groups R 6 are independent substituents.
- This subset therefore contains compounds in which the E unit is di- or t ⁇ - substituted, and in the disubstituted case any rings formed by one or both R 6 groups are spiro ⁇ gs, and in the t ⁇ substituted case, the R 6 groups may form either spiro or nonspiro ⁇ ngs.
- the invention in another of its embodiments, relates to compounds of generalized formula (L) in which the number of substituents m on the E unit is 1 or 2; and when m is 1 , the group R 6 constitutes a nonspiro ring; and when m is 2. both groups R 6 together constitute a nonspiro ⁇ ng or one group R 6 is an independent substituent and the other constitutes a nonspiro ⁇ ng.
- This subset therefore contains compounds in which the E unit cames one or two substituents R 6 , and at least one of these substituents is involved in a nonspiro ⁇ ng.
- a is 0, 1 , or 2
- b is 0 or 1
- c is 0 or 1
- d is 0 or 1
- c + d is 0 or 1
- e is 1 - 5
- f is 1 - 4
- g is 3
- Each group R 14 is independently selected from the group consisting of alkvl of 1 - 9 carbons; arylalkyi in which the alkyl portion contains 1 - 7 carbons and the aryl portion contains 6 - 10 carbons, alkenyi of 2 - 9 carbons, aryl-substituted alkenyi in which the alkenyi portion contains 2 - 4 carbons and the aryl portion contains 6 - 10 carbons; alkynyl of 2 -
- n 0
- y is 0 (i.e., there is no ⁇ ng structure), 2 (cyclobutyl), or 3 (cyclopentyl), r is 0-6.
- Z is (CH : ) 7 or (CH 2 ).-C 6 H 4 -(CH 2 ) f , wherein e is 0-1 and f is 1 -6. and R 15 is -H, -Cl. -OMe or
- R 4 is one of the following: halide. alkyl of 1 -6 carbons, OR, NR . NO :
- stereoisomers which possess inhibitory activity against an MMP, regardless of their stereoisome ⁇ c designauons. as well as mixtures of stereoisomers m which at least one member possesses inhibitory activity.
- the compounds of the invention may be prepared by use of known chemical reactions and procedures. Nevertheless, the following general preparative methods are presented to aide the reader in synthesizing the inhibitors. More detailed procedures for particular examples are presented below in die experimental section. In the general methods the following generic descriptions apply.
- the group designated P represents a protecting group. It may be appreciated by one skilled in the act that a variety of different protecting groups may be used to protect a potentially reactive functional group (e.g.
- the group designated X represents a leaving group
- a leaving group It is well known to those skilled in the an that several different functional groups such as halides, mesylates, tosylates and triflates may serve as a leaving groups. It is also known that the choice of a particular leaving group typically depends on such factors as the reactivity of the nucleophile, stability of the compound and ease of synthesis.
- the compounds of the invention where E does not contain a ring are conveniently prepared using an ( ⁇ -halomethyl ketone and a substituted malonate derivative.
- intermediate CIII can be prepared from methyl ketone CII via the corresponding silyl enol ether by treatment with N-bromosuccinimide (NBS).
- NBS N-bromosuccinimide
- the silylenol ether is conveniently prepared from the methyl ketone by treatment with triniethylsilylchlotide (TMSCI) and a base like lithium hexamethyldisilazide (LHMDS).
- TMSCI triniethylsilylchlotide
- LHMDS lithium hexamethyldisilazide
- intermediate CVI can simply be deprotected and decarboxylated using well-known procedures to give target compound CVHI.
- the conditions used to deprotect intermediate CVI will depend on the type of protecting group used.
- Some convenient protecting groups used to synthesize the compounds of the invention include methyl, allyl, benzyl and tert-butyl. Methods to incorporate and remove these groups are well-known to those skilled in the art (see above reference). The choice of protecting group used in the synthesis will depend on such factors as functional group compatibility, ease of synthesis and availability of starting materials.
- an intermediate sidechain Y can be used.
- a protected ethanol group such as CH 2 CH 2 OTBS can be conveniently inco ⁇ orated as this handle.
- TBSOCH 2 CH 2 Br can be prepared from HOH 2 CH 2 Br by methods well-known to those skilled in the art.
- the protecting group can be removed to provide the corresponding alcohol which may be converted to phenyl ethers or a variety of heteroatom substituted derivatives used to generate sidechain Q via the Mitsunobu reaction.
- Alcohol MIH is eliminated via base treatment of its mesylate using conditions well known to those skilled in the art to yield olefin MTV Ozonolysis of MTV (workup with methvsulfide) yields aldehyde MV Alternatively, treatment with OsO 4 followed by H ⁇ 10 6 converts MIV to MV
- Suitable pharmaceutical K acceptable salts of the compounds of the present include addition salts formed with organic or inorganic bases
- the salt forming ion de ⁇ ved from such bases can be metal ions, e g , aluminum, alkali metal ions, such as sodium or potassium, alkaline earth metal ions such as calcium or magnesium, or an amine salt ion. of which a number are known for this purpose Examples include ammonium salts, arylalkvlamines such as dibenzylamine and ⁇ ⁇ -dibenzylethyienediamine. lower alkylamines such as methylamine, .-butylamine, procaine.
- lower aikylpipe ⁇ dines such as ⁇ -ethylpipe ⁇ dine cycloalkvlamines such as cyclohexylamine or d ⁇ c ⁇ ciohexylarrune. 1 -adamantylam ⁇ ne. benzathme. or salts de ⁇ ved from amino acids like arginine.
- physiologically acceptable salts such as the sodium or potassium salts and the ammo acid salts can be used medicinally as desc ⁇ bed below and are preferred
- these and oU er salts which are not necessa ⁇ ly physiologically acceptable are useful in isolating or pu ⁇ fying a product acceptable for the purposes desc ⁇ bed below
- the use of commercially available enantiome ⁇ cally pure amines such as (-t-)-c ⁇ nchonme in suitable solvents can yield salt crystals of a single enatiomer of the invention compounds, leaving the opposite enantiomer in solution in a process often referred to as "classical resolution " As one enantiomer of a given mvention compound is usually substantially greater in physiological effect than its antipode.
- this active isomer can thus be found pu ⁇ fied in either the crystals or the liquid phase.
- the salts are produced by reacting the acid form of the invention compound with an equivalent of the base supplying the desired basic ion in a medium in which the salt precipitates or in aqueous medium and then lyophilizing.
- the free acid form can be obtained from the salt by conventional neutralization techniques, e.g.. with potassium bisulfate. hydrochio ⁇ c acid. etc.
- the compounds of the present invention have been found to inhibit the matnx metalloproteases MMP-3. MMP-9 and MMP-2. and to a lesser extent MMP-1 , and are therefore useful for treating or preventing the conditions referred to in the background section.
- MMPs metalloproteases
- MMP-9 and MMP-2 MMP-9 and MMP-2.
- MMP-1 MMP-1
- compounds of the invention should also inhibit such other MMPs to varying degrees.
- Varying the substituents on the biaryl portions of the molecules, as well as those of the propanoic or butanoic acid chains of the claimed compounds has been demonstrated to affect the relative inhibition of the listed MMPs.
- compounds of this general class can be "tuned" by selecting specific substituents such that inhibition of specific MMP(s) associated with specific pathological conditions can be enhanced while leaving non-involved MMPs less affected.
- the method of treating matnx metal loprotease-mediated conditions may be practiced in mammals, including humans, which exhibit such conditions.
- inhibitors of the present invention are contemplated for use in vete ⁇ nary and human applications. For such purposes, they will be employed in pharmaceutical compositions containing active mgred ⁇ ent(s) plus one or more pharmaceutically acceptable carriers, diluents, fillers, binders, and other excipients, depending on the administration mode and dosage form contemplated.
- Administration of the inhibitors may be by any suitable mode known to those skilled in the art.
- suitable parenteral administration include intravenous, intraarticular, subcutaneous and intramuscular routes.
- Intravenous administration can be used to obtain acute regulation of peak plasma concentrations of the drug Improved half-life and targeting of the drug to the joint cavities may be aided by entrapment of the drug in liposomes. It may be possible to improve the selectivity of posomal targeting to the joint cavities by incorporation of ligands into the outside of the liposomes that bind to synovial-specific macromolecules Alternatively intramuscular, intraarticular or subcutaneous depot injection with or without encapsulation of the drug into degradable microspheres e g .
- comp ⁇ sing poly(DL-lact ⁇ de-co-glycol ⁇ de) may be used to obtain prolonged sustained drug release
- an l p implanted reservoir and septum such as the Percuseal system available from Pharmacia Improv ed convenience and patient compliance may also be achieved by the use ot either injector pens (e g the Novo Pin or Q-pen) or needle -free jet injectors (e g from Bioject.
- Prolonged zero-order or other precisely controlled release such as pulsatile release can also be achieved as needed using implantable pumps with delivery of the drug through a cannula into the synovial spaces
- implantable pumps with delivery of the drug through a cannula into the synovial spaces
- Examples include the subcutaneously implanted osmotic pumps available from ALZA. such as the ALZET osmotic pump
- Nasal delivery may be achieved by incorporation of the drug into bioadhesive paniculate earners ( 200 um) such as those compnsing cellulose, polvacrvlate or polycarbophil. in conjunction with suitable absorption enhancers such as phospholipids or acylcamitines Available systems include those developed by DanBiosys and Scios Nova
- Oral delivery may be achieved by incorporation of the drug into tablets, coated tablets, dragees. hard and soft gelatine capsules, solutions, emulsions or suspensions. Oral delivery may also be achieved by incorporation of the drug into enteric coated capsuies designed to release the drug into the colon where digestive protease activity is low Examples include the OROS-CT'OsmetTM and PULSINCAPTM systems from ALZA and Scherer Drug Delivery Systems respectively.
- Rectal delivery may be achieved by incorporation of the drug into supposito ⁇ es.
- vanous therapeutically inert, inorganic or organic earners well known to those skilled in the art.
- examples of these include, but are not limited to, lactose, com starch or derivatives thereof, talc, vegetable oils, waxes, fats, polyols such as polyethylene glycol. water, saccharose, alcohois. glyce ⁇ n and the like. Vanous preservatives, emulsifiers. dispersants. flavorants. wetting agents, antioxidants.
- sweeteners, colorants, stabilizers, salts, buffers and the like are also added, as required to assist in the stabilization of the formulation or to assist in increasing bioavailabihty of the active ⁇ ngred ⁇ ent(s) or to yield a formulation of acceptable flavor or odor in the case of oral dosing.
- the amount of the pharmaceutical composition to be employed will depend on the recipient and the condition being treated The requisite amount may be determined without undue experimentation by protocols known to those skilled in the art. Alternatively, the requisite amount may be calculated, based on a determination of the amount of target enzyme which must be inhibited in order to treat the condition.
- the matrix metalloprotease inhibitors of the invention are useful not only for treatment of the physiological conditions discussed above, but are also useful in such activities as purification of metalloproteases and testing for matnx metalloprotease activity
- activity testing can be both m vitro using natural or synthetic enzyme preparations or in vivo using, for example, animal models in which abnormal destructive enzyme levels are found spontaneously (use of genetically mutated or transgenic ammals) or are induced by admimstration of exogenous agents or by surgery which disrupts joint stability
- Step 2 A one-necked, 50-mL, round-bottomed flask equipped with a rubber septum and an argon needle inlet was charged with 12 mL THF. t ⁇ methylsilyl chlo ⁇ de (0 83 ml. 0 710 g, 6.54 mmol). lithium hexamethyldisilazide (6.50 ml. 1.0 M in THF, 6.50 mmol), and cooled to -78 °C while a solution of 2-dodecanone (1.19 g. 6.46 mmol) in 8.0 ml THF was added dropwise over a period of 30 mm via cannula. The resulting mixture was stirred at -78 °C for 30 min.
- Step 3 A one-necked. 25 -mi. round-bottomed flask equipped with a rubber septum and an argon needle inlet was charged with 3 ml of THF and the product of step 1 (314 mg. 0.978 mmol). The resulting mixture was cooled to 0 °C and sodium t-butoxide (88.0 mg, 97% pure. 0.888 mmol) was added. .After 30 mm. a solution of the product of step 2 (250 mg, 0.950 mmol) in 3 ml of THF was added dropwise via synnge. The resulting mixture was allowed to warm to room temperature and stirred for 16 h.
- Step 4 Preparation of Example 1.
- a one-necked. 154-mL. round-bottomed flask equipped with a rubber septum and an argon needle inlet was charged with 2 mL of dioxane.
- the product of step 3 ( 300 mg. 0.556 mmol).
- pyrrolidine (0.12 ml, 0.102 g, 1 44 mmol).
- tetrak ⁇ s(mphenylphosp ⁇ ne)pallad ⁇ um 10.0 mg. 0.0086 mmol.
- the resulting mixture was exposed to a slight vacuum to degas the solution and argon was reintroduced.
- the reaction mixture was stirred at room temperature for 12 h.
- Example 1 The above methods for the preparation of Example 1 were used to prepare the following examples (TABLE I) using the appropriate bromoketones in step 3. TABLE I
- the reacuon mixture was diluted with a 1 1 mixture of hexane:ethyl acetate (150 ml), washed with a 50 mL portion of saturated NaHCOv and washed with a 50 mL portion of b ⁇ ne
- Step 1 A solution of 4-(4-methoxyphenyl)-buty ⁇ c acid (3 04 g, 15 4 mmol) in CH,C1 , (45 mL) was treated with oxalyl chlonde (1 1 6 mL, 2.0 M soln. in dichloromethane) and DMF ( 1 drop) The solution was heated to reflux for 2 h. cooled to 0°C and treated with an excess of diazomethane (ether soln.). After stiirmg an additional 30 mm. excess 4 M HCI (soln.
- Step 2 A solunon of sodium hydnde (6 35 g. 264 mmol) in THF (500 mL) was treated with diethyl malonate (47.35 mL, 312 mmol) After stirnng for 2 h. (2-bromoethyl)benzene (32.8 mL, 240 mmol) was carefully added to the reaction mixture. Following the addition, the solution was heated to a gentle reflux for 16 h. cooled to 0°C and quenched with 2 N HCI . The resulting solution was concentrated under reduced pressure, diluted widi EtOAc and washed with satd. aq. NaCl . The organic layer was dried over N!.:SO 4 and concentrated.
- Step 3 A solution of malonate from step 2 (3.50 g, 13.2 mmol) in DME (5 mL) was treated with NaOEt (0.67 g, 9.9 mmol) and stirred for 30 mm. While the solution was stimng, a separate flask containing a solution of the ⁇ -chloro ketone from step 1 (0.95 g, 4.2 mmol) in DME (5 mL) was treated witii Lil (0.62 g, 4.6 mmol), stirred for 15 min. and cannulated into the first solution.
- Step 4 Preparation of Example 7.
- a solution of the diester from step 3 (0 19 g, 0 42 mmol) in ethanol (3 mL) was treated with 2 N NaOH (0.5 mL) and stirred at room temperature After stimng for 16 h. the soln was concentrated under reduced pressure, diluted with ethyl acetate, and washed with aq K. : CO
- the aqueous layer was acidified to pH 1 with 2 N HCI . and extracted with ethyl acetate The orgamc layer was dned over MgSO 4 .
- Example VU TABLE ⁇
- the P218 quenched fluorescence assay ( icrofluoromet ⁇ c Profiling Assay) is a modification of that o ⁇ gmally desc ⁇ bed by Kmght, et al . FEBS Lett. 296. 263, 1992 for a related substance and a va ⁇ ety of matnx metalloproteinases (MMPs) in cuvettes The assay was run with each invenuon compound and the three MMPs. MMP-3. MMP-9 and MMP-2. analyzed in parallel, adapted as follows for a 96-well microtiter plate and a Hamilton AT* workstation.
- P218 is a synthetic substrate containing a 4-acetyl-7-methoxycouma ⁇ n ( MCA) group in the N-terminal position and a 3-[2, 4-d ⁇ n ⁇ trophenyl]-L-2,3-d ⁇ am ⁇ nopropionyl (DPA) group internally. This is a modification of a peptide reported by Knight ( 1992) that was used as a substrate for matnx metalloproteinases. Once the P218 peptide is cleaved (putative clip site at the Ala-Leu bond), the fluorescence of the MCA group can be detected on a fluorometer with excitation at 328 nm and emission at 393 nm. P218 is currently being produced BACHEM exclusively for Bayer. P218 has the structure: H-MCA-Pro-Lys-Pro-Leu- _/ ⁇ -Zeu-DPA-Ala-Arg-NH2 (MW 1332.2)
- Pro-MMP-3 Pro-MMP-3 at 1.72 ⁇ M (100 ⁇ g/mL) in 5 mM Tris at pH 7.5. 5 M CaCl : . 25 mM NaCl. and 0 005% Brij-35 MMP-3) activation buffer) was activated by incubation with TPCK (N-tosyl-(L)-phenylalanine chloromethyl ketone) trypsin (1 : 100 w/w to pro- MMP-3) at 25 °C for 30 min. The reaction was stopped by addition of soybean trypsin inhibitor (SBTI; 5 : 1 w/w to trypsin concentration). This activation protocol results in the formation of 45 kDa active MMP -3. which still contains the C-terminal portion of the enzyme.
- TPCK N-tosyl-(L)-phenylalanine chloromethyl ketone
- Pro-MMP-2 Human pro-gelatinase A (pro-MMP-2) was prepared using a vaccinia expression system according to the method of Fridman. et ai.. J. Biol. Chem. 267. 15398 (1992).
- Pro-MMP-2 Activation of Pro-MMP-2.
- Pro-MMP-2 at 252 mg'mL was diluted 1 :5 to a final concentration of 50 ⁇ g/mL solution in 25 mM Tris at pH 7.5, 5 mM CaCl,, 150 mM NaCl, and
- MMP-2 activation buffer 0.005%o Brij-35 (MMP-2 activation buffer).
- /7-Ammophenylmercuric acetate (APMA) was prepared in 10 mM (3.5 mg/mL) in 0.05 NaOH. The APMA solution was added at 1/20 die reaction volume for a final AMPA concentration of 0.5 mM, and die enzyme was incubated at 37 °C for 30 min.
- Activated MMP-2 (15 mL) was dialyzed twice vs. 2 L of MMP-2 activation buffer (dialysis membranes were pre-treated with a solution consisting of 0.1% BSA in MMP-2 activation buffer for 1 min, followed by extensive H : O washing).
- the enzyme was concentrated on Centricon concentrators (concentrators were also pre-treated with a solution consisting of 0.1 % BSA in MMP- 2 activation buffer for 1 min.. followed by washing with H : 0, then MMP-2 activation buffer) with re-dilution followed by re-concentration repeated twice.
- the enzyme was diluted to 7.5 mL (0.5 times the o ⁇ ginal volume) with MMP-2 activation buffer.
- Recombinant Human Pro-MMP-9 Human pro-gelatinase B (pro-MMP-9) derived from U937 cDNA as described by Wilhelm, et al. J. Biol. Chem. 264, 17213 (1989) was expressed as the full-length form using a baculovirus protein expression system. The pro-enzyme was purified using methods previously described by Hibbs. et al. J. Biol. Chem. 260, 2493 (1984).
- Pro-MMP-2 20 ⁇ g/mL in 50 mM Tris at pH 7.4, lOmM CaCl 2 .
- 150 mM NaCl, and 0.005% Brij-35 MP-9 activation buffer was activated by incubation with 0.5 mM acetate (APMA) for 3.5 h at 37 °C.
- the enzyme was dialyzed against the same buffer to revmove the APMA.
- Hamiltion Microlab AT Plus The MMP-Profiling Assay is performed robotically on a Hamilton MicroLab AT Plus*.
- the Hamilton is programmed to: ( 1 ) serially dilute up to 1 1 potential inhibitors automatically from a 2.5 mM stock in 100% DMSO; (2) distribute substrate followed by inhibitor into a 96 well Cytofluor plate; and (3) add a single enzyme to the plate with mixing to start the reaction. Subsequent plates for each additional enzyme are prepared automatically by beginning the program at the substrate addition point, remixing the diluted inhibitors and beginning the reaction by addition of enzyme. In this way, all MMP assays were done using die same inhibitor dilutions. Milhpore Cytofluor II Following incubation, the plate was read on a Cytofluor II fluorometnc plate reader wi excitation at 340 nM and emission at 395 nM with the ga set at 80 Buffers:
- Microfluoromemc Reaction Buffer Dilution of test compounds, enzymes, and P218 substrate for the microfluoromet ⁇ c assay were made in microfluoromet ⁇ c reaction buffer consisting of 50 mM 2-(N-morphol ⁇ no)ethanesulfon ⁇ c acid (MES) at pH 6.5 widi 10 mM CaCl 2 , 150 mM NaCl. 0.005% Brij-35 and 1 % DMSO Methods:
- MES 2-(N-morphol ⁇ no)ethanesulfon ⁇ c acid
- MMP Microfluoromemc Profiling Assay The assay is done with a final substrate concentration of 6 uM P218 and approximately 5 to 8 nM MMP with vanable drug concentrations.
- the Hamilton is programmed to senally dilute up to 1 1 compounds from a 2.5 mM stock (100% DMSO) to l Ox the final compounds concentrations in the assay Initially, the instrument delivers various amounts of microfluoromentnc reaction buffer (MRB) to a 96 tube rack of 1 ml Marsh dilution tubes. The instrument then picks up 20 ⁇ l of inhibitor (2.5 mM) from the sample rack and mixes it with a buffer in row A of the Marsh rack, resulting m a 50 ⁇ M drug concentration. The inhibitors are then serially diluted to 10. 5, 1 , 2. .05 and 01 ⁇ M.
- MRB microfluoromentnc reaction buffer
- Position 1 on die sample rack contains only DMSO for the "enzyme-only" wells in the assay, which results in no inhibitor in column 1, rows A through H.
- the instrument then dist ⁇ butes 107 ⁇ l of P218 substrate (8.2 ⁇ M in MRB) to a single 96 well cytofluor microtiter plate.
- the instrument re-mixes and loads 14.5 ⁇ l of diluted compound from rows A to G in the Marsh rack to corresponding rows in die microtiter plate.
- the plate After addition and mixing of the enzyme, the plate is covered and incubated for 25 mm. at 37 °C. Add onal enzymes are tested in the same manner by beginning the Hamilton program with the distnbution of P218 substrate to the microtiter plate, followed by re-mixing and dist ⁇ bution of the drug from the same Marsh rack to the microtiter plate. The second (or third, etc.) MMP to be tested is then distributed from a reagent rack to the microtiter plate with mixing, p ⁇ or to cove ⁇ ng and incubation This is repeated for all additional MMP's to be tested.
- MMPs (one 96 well plate per MMP) were calculated simultaneously.
- the percent inhibition is determination for each drug concentration by compa ⁇ ng the amount of hydrolysis (fluorescence units generated over 25 minutes of hydrolysis) of wells containing compound widi the "enzyme only" wells in column 1 Following subtraction of the background the percent inhibition was calculated as:
Abstract
The present invention provides pharmaceutical compositions and methods for treating certain conditions comprising administering an amount of a compound or composition of the invention which is effective to inhibit the activity of at least one matrix metalloprotease, resulting in achievement of the desired effect. The compounds of the present invention are either of generalized formula (I) wherein y is 0, 2, or 3, r is 0-6, Z is (CH2)7 or (CH2)e-C6H4-(CH2)f, wherein e is 0-1 and f is 1-6, and R15 is -H, -Cl, -OMe or (a), (b) wherein n is 0-4, R17 is C2H5, allyl, benzyl, and R16 is (c) wherein t is 0-1, x is 0-4, and R4 is one of the following: halide, alkyl of 1-6 carbons, OR, NR¿2?, NO2 (R = H or alkyl of 1-6 carbons). These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, demyelating diseases of the nervous system, tumor metastasis or degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from atherosclerotic plaque rupture. The present invention also provides pharmaceutical compositions and methods for treating such conditions.
Description
Substituted Oxobutyric Acids as Matrix Metalloproteinase Inhibitors
BACKGROUND OF THE INVENTION Field of the Invention
This invention relates to enzyme inhibitors, and more particularly, to novel oxoburyπc acids compounds or derivatives thereof useful for inhibiting matnx metalloproteases. Description of the Related Art
The matnx metalloproteases (a.k.a. matnx metalloendo-protemases or MMPs i are a famrn of zinc endoproteinases which include, but are not limned to. interstitial collagena≤e (a.k.a.
MMP- 1 ). stromelysin (a.k.a.. proteoglycanase. transin. or MMP-3), gelatinase A (a.k.a.. 72kDa-geiaunase or MMP-2) and gelatinase B (a.k.a.. 95kDa-gelatιnase or MMP-9). These MMPs are secreted by a variety of cells including fibroblasts and chondrocytes. along with natural proteinaceous inhibitors known as TTMPs (Tissue Inhibitor of MetalloProteinase). All of these MMPs are capable of destroying a vanery of connective tissue components of articular cartilage or basement membranes. Each MMP is secreted as an inactive proenzyme which must be cleaved in a subsequent step before it is able to exert its own proteolytic activity In addition to the matnx destroying effect, certain of these MMPs such as MMP-3 have been implemented as the in vivo activator for other MMPs such as MMP-1 and MMP-9 (Ito. et al.. Arch Biochem Biophys. 67, 21 1 ( 1988); Ogata, et al.. J. Biol. Chem., 267, 3581 (1992)). Thus, a cascade of proteolytic activity can be initiated by an excess of MMP-3. It follows that specific MMP-3 inhibitors should limit the activity of other MMPs that are not directly inhibited by such inhibitors.
It has also been reported that MMP-3 can cleave and thereby inactivate the endogenous inhibitors of other protemases such as elastase (Wmyard. et al . FEBS Lens 229, 1 , 91 (1991 )) Inhibitors of MMP-3 could thus influence the activity of other destructive protemases by modifying the level of their endogenous inhibitors A number of diseases are thought to be mediated by excess or undesired matπx-destroying metalloprotease activity or by an imbalance in the ratio of the MMPs to the TIMPs These include a) osteoarthπus (Woessner, et al , J. Biol Chem , 259(6). 3633 (1984), Phadke. et al . J Rheumatol 10, 852 (1983)), b) rheumatoid arthπtis (Mullins, et al.. Biochim, Biophys Acta 695, 1 17 (1983). Woo Hey, et al , Arthπtis Rheum 20, 1231 (1977), Gravallese, et al., Arthπtis Rheum 34, 1076 ( 1991 )) c) septic arthπtis (Williams, et al . . rthπtis Rheum H, 533 ( 1990)), d) tumor metastasis
(Reich, et al . Cancer Res , 48, 3307 (1988). and Matπsian. et al., Proc Nat'l Acad Sci . USA £3, 9413 (1986)), e) peπodontal diseases (Overall, et al., J Peπodontal Res 22, 81 (1987)), cornea! uiceration (Bums, et al., Invest. Opthalmol Vis Sci 2 _, 1569 (1989)), g) protetnuna (Baπcos. et al.. Biochem. J 254. 609 (1988)), h) coronary thrombosis from atherosclerotic plaque rupture (Henney, et al.. Proc Nat'l Acad Sci.. USA 88, 8154 ( 1991 )), I) aneurysmal aortic disease (Vine, et al . Can Sci & 233 (1991)), j) birth control (Woessner, et al., Steroids 54, 491 (1989)). k) dystrophobic epidermolysis bullosa (Kronberger. et al . J Invest Dermatol 79, 208 ( 1982)). and 1) degenerative cartilage loss following traumatic joint injury, m) conditions leading to inflammatory responses, osteopenias mediated by MMP activity, n) tempero mandibular joint disease, o) demyelating diseases of the nervous system (Chantry, et al., J Neurochem £0, 688 (1988))
The need for new therapies is especially important in the case of arthπtic diseases The pπmary disabling effect of osteoarthπtis (OA). rheumatoid arthπtis (RA) and septic arthπtis is the progressive loss of articular cartilage and thereby normal joint function. No marketed
pharmaceutical agent is able to prevent or slow this cartilage loss, although nonsteroidal anti- inflammatory drugs (NS AIDs) have been given to control pain and swelling. The end result of these diseases is total loss of joint function which is only treatable by joint replacement surgery. MMP inhibitors are expected to halt or reverse the progression of cartilage loss and obviate or dela> surgical intervention.
Proteases are cπtical elements at several stages in the progression of metastatic cancer. In this process, the proteolytic degradation of structural protem in the basal membrane allows for expansion of a tumor in the pπmary site, evasion from this site as well as homing and invasion in distant, secondary sues. Also, tumor induced angiogenesis is required for tumor growth and is dependent on proteolytic tissue remodeling Transfection experiments with vanous types of proteases have shown that the matnx metalloproteases play a dominant role in these processes in particular gelaunases A and B (MMP-2 and MMP-9, respectively). For an overview of this field see Mullins. et al.. Biochim. Biophys. Acta 695, 177 (1983); Ray. et al., Eur. Respir. J. 1, 2062 (1994); Birkedal-Hansen, et al., Crit. Rev Oral Biol. Med. 4, 197 (1993). Furthermore, it was demonstrated that inhibition of degradation of extracellular matnx by the native matnx metal loprotease inhibitor TIMP-2 (a protein) arrests cancer growth (DeClerck, et al.. Cancer Res. 52, "701 (1992)) and that TTMP-2 inhibits tumor-induced angiogenesis in expeπmental systems (Moses, et al. Science 248, 1408 (1990)). For a review, see DeClerck. et al., Ann. N Y Acad. Sci. 732, 222 ( 1994). It was further demonstrated that the synthetic matnx metal loprotease inhibitor batimastat when given lntraperitoneally inhibits human colon tumor growth and spread in an orthotopic model in nude mice (Wang, et al. Cancer Res. 54, 4726 (1994)) and prolongs the survival of mice bearing human ovarian carcinoma xenografts (Davies, et. al., Cancer Res. £3, 2087 (1993)). The use of this and related compounds has been described in Brown, e al.. WO-9321942 A2 (931 1 1 1 ).
There are several patents and patent applications claiming the use of metalloprotemase inhibitors for the rctardauon of metastatic cancer, promoting rumor regression, inhibiting cancer cell proliferation, slowing or preventing cartilage loss associated with osteoarthπtis or for treatment of other diseases as noted above (e.g. Levy, et al., WO-9519965 A 1. Beckett, et al . WO-9519956 A ! . Beckett et al., WO-9519957 Al . Beckett et al., WO-9519961 A l , Brown, et al., WO-9321942 A2.
Cnmmin. et al . WO-9421625 A 1. Dickens, et al., U.S. Pat No 4.599,361 , Hughes, et al., U.S Pat No 5.190.937; Broadhurst, et al., EP 574758 A 1 , Broadhurst, et al., EP 276436; and Myers, et al.. EP 520573 Al The preferred compounds of these patents have peptide backbones with a zinc complexmg group (hydroxamic acid, thiol. carboxylic acid or phosphinic acid) at one end and a vaπety of sidechains. both those found in the natural ammo acids as well as those with more novel functional groups Such small peptides are often poorly absorbed, exhibiting low oral bioavailabi ty. They are also subject to rapid proteolytic metabolism, thus having short half lives. As an example, baumastat. the compound descπbed in Brown, et al., WO-9321942 A2. can only be given intrapeπtoneally. Others have disclosed a seπes of biphenyl-containing carboxylic acids, illustrated by the compound shown below, which inhibit neural endopeptidase (NEP 24 11 ), a membrane-bound zinc metalloprotease (Stanton. et al., Bioorg. Med. Chem. Lett 4, 539, 1994. Lombaert. et al.. Bioorg Med. Chem. Lett. 4, 2715 (1994), Lombaert. et al., Bioorg. Med. Chem Lett 5, 145 ( 1995), Lombaert. et al., Bioorg. Med. Chem. Lett. 5, 151 ( 1995))
It has been reported that N-carboxyalkyl derivatives containing a biphenylethylglycine. illustrated by the compound shown below, are inhibitors of stromelysin- 1 (MMP-3). 72 kDA gelatinase (MMP-2) and collagenase (Durette, et al., WO-9529689).
It would be desirable to have effective MMP inhibitors which possess improved bioavailabihty and biological stability relative to the peptide-based compounds of the prior art, and which can be optimized for use against particular target MMPs. Such compounds are the subject of the present application.
The development of efficacious MMP inhibitors would afford new therapies for diseases mediated by the presence of. or an excess of MMP activity, including osteoarthπtis. rheumatoid arthritis, sepuc arthritis, tumor metastasis, peπodontal diseases, cornea! uicerations. and proteinuria. Several inhibitors of MMPs have been described in the literature, including thiols (Beszant. et al.,
J. Med. Chem. 36, 4030 (1993)), hydroxamic acids (Wahl. et al. Bioorg. Med. Chem. Lett. 5, 349 ( 1995); Conway, et al. J. Exp. Med. L82, 449 ( 1995); Porter, et al., Bioorg. Med. Chem. Lett. 4, 2741 (1994); Tomczuk, et al.. Bioorg. Med. Chem. Lett. 5, 343 (1995); Casteihano, et al., Bioorg. Med. Chem. Lett. 5, 1415 (1995)), phosphorous-based acids (Bird, et al. J. Med. Chem. H, 158
(1994), Morphy, et al.. Bioorg Med Chem Lett 4, 2747 (1994), Kortyiewicz. et al , J Med Chem
21, 263 (1990)), and carboxylic acids (Chapman, et al J Med Chem 36, 4293 (1993). Brown, et al J Med Chem 37, 674 (1994), Morphy, et al . Bioorg Med Chem Lett 4. 2747 ( 1994), Stack, et al , .Arch Biochem Biophys 287, 240 (1991 ), Ye. et al , J Med Chem 37, 206 (1994). Grobeiny, et al . Biochemistry 24, 6145 (1985), Mookhtiar. et al , Biochemistry 2, 4299 (1988))
However, these inhibitors generally contain peptidic backbones, and thus usually exhibit low oral bioacmity due to poor absorption and short half lives due to rapid proteolvsis Therefore, there remains a need for improved MMP inhibitors
SUMMARY OF THE INVENTION
This invention provides compounds having matnx metal loprotease inhibitory activity These compounds are useful for inhibiting matnx metalloproteases and, therefore, combating conditions to which MMPs contribute Accordingly, the present invention also provides pharmaceutical compositions and methods for treating such conditions The compounds descπbed relate to a method of treating a mammal compnsmg admirusteπng to the mammal a matnx metalloprotease inhibiting amount of a compound according to the invention sufficient to
(a) alleviate the effects of osteoarthπtis, rheumatoid arthntis, septic arthntis, peπodontal disease, comeal ulceration, proteinuπa, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteoperuas mediated by MMP activity, tempero mandibular joint disease, demyelatmg diseases of the nervous system,
(b) retard tumor metastasis or degenerative cartilage loss following traumatic joint injury;
(c) reduce coronary thrombosis from athrosclerotic plaque rupture; or
(d) effect birth control
The compounds of the present invention are also useful scientific research tools for studying funcuons and mechanisms of action of matnx metalloproteases in both in vivo and in vitro systems
Because of their MMP-inhibmng activity, the present compounds can be used to modulate MMP action, thereby allowing the researcher to observe the effects of reduced MMP activity in the expeπmental biological system under study
This invention relates to compounds having matnx metal loprotease inhibitory activity and the generalized formula
A-D-E-G (L) A represents alkyl. allyl-, benzyioxy-, or 3-propynyl alkyl groups as well as the structure
R -^ ^Z-CH2 where Z = (CH:)t-QH4-(CH:)f or (CH:)g. e = 0-8, f = 0-5, g = 0-14 and wherer is 0-6 Rl 5 may be -H, -Cl. -OMe or
wherein n is 0-4. R'7 is -C:H}. -allyl. or -benzyl.
In the generalized formula (L), D represents
\ \ \ \ ,H \ ,H
C=0 C = NOH C =S Cx C.
/ / / OH / H
In the generalized formula (L), E represents a chain of n carbon atoms beanng m substituents R6 in which the R6 groups are independent substituents. or constitute spiro or nonspiro nngs. Rings may be formed in two ways: a) two groups R6 are joined, and taken together with the chain atom(s) to which the two Rβ group(s) are attached, and any intervening chain atoms, constitute a 3 - 7 embered πng, or b) one group R6 is joined to the chain on which this one group R6 resides, and taken together with the chain atom(s) to which the R6 group is attached, and any intervening chain
atoms, constitutes a 3 - 7 membered ring. The number n of carbon atoms in the chain is 2 or 3, and the number m of R6 substituents is an integer of 1 - 3. The number of carbons in the totality of R6 groups is at least two.
Each group R* is alkyl. alkenyl. alkynyl, aryl, heteroaryl. non-aromatic cyclic, and combmauons thereof optionally substituted with one or more hetero-atoms as described more fully below
In the generalized formula (L). E is a substituted mono- or bicyclic moiety optionally substituted with one or more heteroatoms.
In the generalized formula (L), G represents -CO H, -PO3H;, -M,
m which M represents -C02H, -CONfR"),, or -CO,R12. where R" is H or alkyl of 1 - 4 carbons. R'- IS alkyl of 1 - 4 carbons, and Ru represents any of the side chains of the ! 9 noncyclic naturally occurπng amino acids. Certain embodiments include compounds having matnx metal loproteinase inhibitory activity and the following generalized formula:
R" may be H, Cl, MeO or
wherein n is 0-4, R17 is C:H„ allyl, or benzyl, and R16 is one of
where t is 0-2, x is 0-4 and R" is one of the following: halide, alkyl of 1-6 carbons, OR. NR,. NO: (R = H or alkyl of 1 -6 carbons).
The foregoing merely summanzes certain aspects of the present invention and is not intended, nor should it be construed, to limit the invention in any way. All of the patents and other publications recited in this specification are hereby incoφorated by reference in their entirety.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
More particularly, the compounds of the present invention are mateπals having matnx metalloprotease inhibitory activity and the generalized formula:
A-D-E-G (L) in which A represents alkyl of 9-14 carbons or alkyloxv of 9-18 carbons, or allyloxy-, benzyloxy-, or propynyl- alkyl of 9-18 carbons. A is also represented by the structure:
R ^Z-CH2 where Z = (CH:)e- H4-(CH2)f or (CH2)g, e = 0-8, f = 0-5, g = 0-14 and where r is 0-6. Rl 5 may be -H. -Cl. -OMe or
wherein n is 0-4, R17 is C,H5. allyl, or benzyl.
In the generalized formula (L), D represents the moieties
\ \ \ \ .H \ ,H
C=0 C = NOH C =S Cs C,
/ / / OH / H
Throughout this application, in the displayed chemical structures, an open bond indicates the point at which the structure joins to another group. For example,
where R is
In the generalized formula (L), E represents a chain of n carbon atoms beaπng m substituents R6. referred to as R6 groups or R6 units. The R6 groups are independent substituents, or constitute spiro or nonspiro πngs. Rings may be formed in two ways: a) two groups Rβ are joined, and taken together with the cham atom(s) to which the two R6 group(s) are attached, and any intervening chain atoms, constitute a 3 - 7 membered πng. or b) one group R6 is joined to the chain on which this one group R6 resides, and taken together with the chain atom(s) to which the R 6group is attached, and any intervening chain atoms, constitutes a 3 - 7 membered πng. The number n of carbon atoms in the chain is 2 or 3, and the number m of R6 substituents is an integer of 1 - 3. The number of carbons in the totality of R* groups is at least two.
Each group R6 is independently selected from the group consisting of the substituents listed below as items 1) - 14): 1) alkyl of 1 - 10 carbons;
2) aryl of 6 - 10 carbons;
3) heteroaryl compπsing 4 - 9 carbons and at least one N, O. or S heteroatom;
4) arylalkyl in which the aryl portion contains 6 - 10 carbons and d e alkyl portion contains 1 - 8 carbons;
5) heteroaryl-alkyl in which the heteroaryl portion compπses 4 - 9 carbons and at least one N, O, or S heteroatom. and the alkyl portion contains 1 - 8 carbons;
6) alkenyi of 2 - 10 carbons;
7) aryl-alkenyl in which the aryl portion contains 6 - 10 carbons and the alkenyi portion contains 2 - 5 carbons;
8) heteroaryl-alkenyl in which the heteroaryl portion compπses 4 - 9 carbons and at least one N, O. or S heteroatom and the alkenyi portion contains 2 -5 carbons.
9) alkynyl of 2 - 10 carbons;
10) aryl-alkynyl in which the aryl portion contains 6 - 10 carbons and the alkynyl portion contains 2 - 5 carbons.
1 1 ) heteroaryl -alkynyl in which the heteroaryl portion compπses 4 - 9 carbons and at least one N. O, or S heteroatom and the alkynyl portion contains 2 - 5 carbons;
12)-(CH;,),R7 in which t is 0 or an integer of 1 - 5 and R7ιs selected from the group consisting of:
as well as corresponding heteroaryl moieαes in which the aryl portion of an arvl-containing R7 group compπses 4 - 9 carbons and at least one N. 0. or S heteroatom In such R7 groups, Y represents O or S. and u is 0, 1. or 2 provided that when R7 is
and the A un t is phenyl. the B un t is phenyiene. m is 1. n is 2. and t is 0, and x is 1 or 2
R1 represents H or alkyl of 1 - 3 carbons R: represents H, alkyl of 1 - 6 carbons, aryl of 6 - 10 carbons, heteroaryl compπsing 4 - 9 carbons and at least one N. O, or S heteroatom. arylalkyi in which the aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 4 carbons, or heteroaryl-alkyl in which the heteroaryl portion compπses 4 - 9 carbons and at least one N, O, or
S heteroatom and the alkyl portion contains 1 - 4 carbons
R5 represents alkyl of 1 - 4 carbons, aryl of 6 - 10 carbons, heteroaryl compπsing 4 - 9 carbons and at least one N, O, or S heteroatom, arylalkyi in which the aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 4 carbons, or heteroaryl-alkyl in which the heteroaryl portion compnses 4 - 9 carbons and at least one N, O, or S heteroatom and the alkyl portion contains
1 - 4 carbons
13) -{CHjXPR'in which v is an interger of 1 to 4, P represents -S-, -S(O)-, -SO:-, or -O- and R1 is selected from the group consisting of alkyl of 1 to 12 carbons, aryl of 6 to
10 carbons, heteroaryl compπsing 4 to 9 carbons and at least one N, O, or S heteroatom, arylalkyi in which the aryl portion contains 6 to 12 carbons and the alkyl portion contains 1 to 4 carbons; heteroaiylalkyl in which the aryl portion contains 6 to 12 carbons and at least one N, O, or S heteroatom and the alkyl portion contains 1 to 4 carbons, -C(O)R9 in which
the R' represents alkyl of 2 to 6 carbons, aryl of 6 to 10 carbons, heteroaryl compπsing 4 to
9 carbons and at least one N, O, or S heteroatom; and arylalkyi in which the aryl portion contains 6 to 10 carbons or is a heteroaryl compπsing 4 to 9 carbons and at least one N, O. or S heteroatom, and the alkyl portion contains 1 to 4 carbons, with the provisos that when R8 is -C(O)R . Z is -S- or -O-, when Z is -0-, R8 may also be -(C„H2qO)-Ri in which q. r. and
R5 are as defined above; and when the A un t is phenyl, the B unit is phenylene. m is 1. n is 2. and v is 0, then x is 1 or 2.
2 carbons. In addiuon. aryl or heteroaryl portions of any of the R6 groups optionally may bear up to two substituents selected from the group consisting of -(CH2\C(R")(R'2)OH, -(CH2),OR". -( CH2\SR".
-(CH2),S(O)R", -(CH2)vS(O),R , ' kCH2χSO,N(R )2, -(CH2χN(R )2. -(CH2)VN( )COR .
-OC(R" )2O- in which both oxygen atoms are connected to the aryl πng, -(CH,).COR".
-(CH^CONfR''^, -(CH2χC02R". -(CH2\OCOR" -halogen. -CHO, -CF3, -NO2, -CN, and -Rι:, in which y is 0 - 4: R" represents H or alkyl of 1 - 4 carbons; and R'2 represents alkyl of 1 - 4 carbons.
In the generalized formula (L). G represents -CO2H. -PO,H2, -M,
O ll \ / O ι ι R l 13 I N-N >'
— C-N-C-M , —C-N-C-M , or — ^ -N
H H N in which M represents -CO:H, -CON(R"):, or -CO:R12. and R'3 represents any of the side chains of the 19 noncyclic naturally occumng ammo acids.
Pharmaceutically acceptable salts of the compounds falling within the generalized formula (L) are also within the invention.
It is to be understood that as used herein, the term "alkyl" means straight, branched, cyclic. and polycyclic materials. The term "haloaikyl" means partially or fully halogenated alkyl groups such as -(CH;)2C1. -CF3 and -C6F13 for example.
In one embodiment the invention relates to compounds of generalized formula CL). wherein n is 2 and m is 1 in the E unit. These compounds thus possess two carbon atoms between the D unit and the G unit, and carry one substituent on this two-carbon chain.
In another of its embodiments, the invention relates to compounds of generalized formula CL) in which the number of substituents m on the E unit is 2 or 3; and when m is 2, both groups R6 are independent substituents, or together constitute a spiro πng. or one group R* is an independent substituent and the other constitutes a spiro πng; and when m is 3. rwo groups R6 are independent substituents and one group R6 constitutes a πng, or two groups R 'constitute a ring and one group R6 is an independent substituent. or three groups R6 are independent substituents. This subset therefore contains compounds in which the E unit is di- or tπ- substituted, and in the disubstituted case any rings formed by one or both R6 groups are spiro ππgs, and in the tπsubstituted case, the R6 groups may form either spiro or nonspiro πngs.
In another of its embodiments, the invention relates to compounds of generalized formula (L) in which the number of substituents m on the E unit is 1 or 2; and when m is 1 , the group R6 constitutes a nonspiro ring; and when m is 2. both groups R6 together constitute a nonspiro πng or one group R6 is an independent substituent and the other constitutes a nonspiro πng. This subset therefore contains compounds in which the E unit cames one or two substituents R6, and at least one of these substituents is involved in a nonspiro πng.
More particularly, representative compounds of generalized formula (L) in which one or more of the substituent groups R6 are involved in formation of nonspiro πngs have E units of the following structures:
in which a is 0, 1 , or 2, b is 0 or 1 , c is 0 or 1 , d is 0 or 1 , c + d is 0 or 1 , e is 1 - 5, f is 1 - 4, g is 3
- 5, h is 2 - 4. l is 0 - 4, j is 0 - 3. k is 0 - 2, the total number of groups R6 is 0. 1 , or 2, U represents O. S. or NR' , and z is 1 or 2, Each group R14 is independently selected from the group consisting of alkvl of 1 - 9 carbons; arylalkyi in which the alkyl portion contains 1 - 7 carbons and the aryl portion contains 6 - 10 carbons, alkenyi of 2 - 9 carbons, aryl-substituted alkenyi in which the alkenyi portion contains 2 - 4 carbons and the aryl portion contains 6 - 10 carbons; alkynyl of 2 -
9 carbons, aryl -substituted alkynyl in which the alkynyl portion contains 2 - 4 carbons and the aryl portion contains 6 - 10 carbons; aryl of 6 - 10 carbons; -COR2; -CO,R3; -CONCR2)^ -(CH^p n which t is 0 or an integer of 1 - 4, and -(CH2).ZRβ in which v is 0 or an integer of 1 to 3, and Z represents -S- or -O- R', R2, R\ R6, R7, and R' have been defined above
Preferred compounds of generalized formula (L) in which one or more of the substituent groups R6 are involved in formation of nonspiro πngs have E units of the following structures:
— >
in which a. b. c. d, ic ->- d), e, g. 1. k. the total number of groups R6, U, and R'4 are as defined above.
Other compounds of generalized formula (L) have R6 units of the following structures:
Most preferred compounds of the general formula (L) include those of the following general formula
wherein y is 0 (i.e., there is no πng structure), 2 (cyclobutyl), or 3 (cyclopentyl), r is 0-6. Z is (CH:)7 or (CH2).-C6H4-(CH2)f, wherein e is 0-1 and f is 1 -6. and R15 is -H, -Cl. -OMe or
R17'° *. . HO^≡≡^ wherein n is 0-4, R17 is -C2H,, -allyl, -benzyl, and R16 is
where x is 0-4. t is 0-2, and R4 is one of the following: halide. alkyl of 1 -6 carbons, OR, NR . NO:
(R = H or alkyl of 1 -6 carbons).
Those skilled in the art will appreciate that many of the compounds of the invention exist
in enantiomeπc or diastereomenc forms, and that it is understood by the art that such stereoisomers generally exhibit different activities in biological systems. This invention encompasses all possible
stereoisomers which possess inhibitory activity against an MMP, regardless of their stereoisomeπc designauons. as well as mixtures of stereoisomers m which at least one member possesses inhibitory activity.
The most prefered compounds of the present invention are as indicated and named in the list below
I) 1 ,3-dihydro- 1 ,3-dioxo-α-(2-oxododecyl)-2H-isoιndole-2-butanoic acid,
II) l ,3-dihydro-l ,3-dioxo-α-(2-oxoundecyl)-2H-isoindole-2-butanoic acid,
III) 1 ,3-dihydro- 1 ,3-dioxo-α-(2-oxotridecyl)-2H-isoindole-2-butanoic acid,
IV) 1 ,3-dihydro-l ,3-dioxo-α-(2-oxotetradecyl)-2H-isoindole-2-butanoic acid, V) 1.3-dihydro-1.3-dioxo-α-(2-oxopentadecyl)-2H-isomdole-2-butanoιc acid,
VI) 1 ,3-dihydro- 1.3-dioxo-α-(2-oxohexadecyl)-2H-isomdole-2-butanoιc acid,
VII) γ-oxo-α-(2-phenylethyl)-benzeneheptanoιc acid.
VIII) γ-oxo-α-(2-phenylethyl)-benzenehexanoιc acid, and EX) γ-oxo-α-(2-phenylethyl)-benzenepentanoιc acid The compounds of the invention may be prepared by use of known chemical reactions and procedures. Nevertheless, the following general preparative methods are presented to aide the reader in synthesizing the inhibitors. More detailed procedures for particular examples are presented below in die experimental section.
In the general methods the following generic descriptions apply. The group designated P represents a protecting group. It may be appreciated by one skilled in the act that a variety of different protecting groups may be used to protect a potentially reactive functional group (e.g. carboxylic acid, alcohol) and that the particular choice will depend upon the reaction conditions required to prepare a given target compound. A description of such protecting groups may be found in: Green and Wuts, Protective Groups in Organic Synthesis, 2nd Ed.. John Wiley and Sons. New York. 1991.
The group designated X represents a leaving group, It is well known to those skilled in the an that several different functional groups such as halides, mesylates, tosylates and triflates may serve as a leaving groups. It is also known that the choice of a particular leaving group typically depends on such factors as the reactivity of the nucleophile, stability of the compound and ease of synthesis.
General Method A - The compounds of the invention where E does not contain a ring are conveniently prepared using an (α-halomethyl ketone and a substituted malonate derivative. The α-halomethyl ketone intermediate CIO (X = Cl, Br) can be conveniently prepared from a carboxylic acid or a methyl ketone. From carboxylic acid Cl, treatment with oxalyl chloride and a catalytic amount of DMF in a solvent like trimethylsilylchloride provides the corresponding acid chloride. Subsequent treatment with excess diazomethane followed by anhydrous HCI or HBr provides intermediate CIE. Alternatively, intermediate CIII can be prepared from methyl ketone CII via the corresponding silyl enol ether by treatment with N-bromosuccinimide (NBS). The silylenol ether is conveniently prepared from the methyl ketone by treatment with triniethylsilylchlotide (TMSCI) and a base like lithium hexamethyldisilazide (LHMDS). General procedures for the preparation of
α-halomethyl ketones are well-known to those skilled in the art. For additional references see Corey, et al., Tetrahedron Lett. 25, 495 (1984) and Reuss, et al., J. Org. Chem. 39, 1785 (1974).
Methods for the preparation of substituted malonate derivatives (CV) are also well-established in the literature. Typically, an unsubstimted malonate derivative is treated with a base like NaH or KOt-Bu in a polar aprotic solvent, and then alkylated with a substituted halide. Similarly, alkylation of mono alkylated intermediate CV with α-halomethyl ketone CHI provides dialkylated intermediate, CVI. It should be appreciated by those skilled in the art that sidechain Y may be the sidechain desired in the final target or a simple handle to further elaborate that portion of the molecule at a latter stage of the synthesis. If sidechain Y is die desired sidechain, then intermediate CVI can simply be deprotected and decarboxylated using well-known procedures to give target compound CVHI. The conditions used to deprotect intermediate CVI will depend on the type of protecting group used. Some convenient protecting groups used to synthesize the compounds of the invention include methyl, allyl, benzyl and tert-butyl. Methods to incorporate and remove these groups are well-known to those skilled in the art (see above reference). The choice of protecting group used in the synthesis will depend on such factors as functional group compatibility, ease of synthesis and availability of starting materials.
If the target compound CXI contains a moiety Q which is sensitive to the reaction conditions used in the alkylation steps then an intermediate sidechain Y can be used. In this case, a protected ethanol group such as CH2CH2OTBS can be conveniently incoφorated as this handle. Intermediate CV with Y = -CHjCH,OTBS can be prepared by using TBSOCH2CH2Br as Y-X in the first alkylation step. TBSOCH2CH2Br can be prepared from HOH2CH2Br by methods well-known to those skilled in the art. The protecting group can be removed to provide the corresponding alcohol which may be converted to phenyl ethers or a variety of heteroatom substituted derivatives used to generate sidechain Q via the Mitsunobu reaction. The Mitsunobu reaction is well known to those
skilled in the art; see Mitsunobu, Synthesis 1 (1981 ), and Hughes, Organic Reactions 42, 335 ( 1992). Alternatively, the alcohol intermdiate is converted to a leaving group such as tosviate or bromide and displaced by an appropriate nucleophile. Several examples of this type of reaction can be found in Norman, et al., J. Med. Chem 37, 2552 (1994). After the desired sidechain Q is incorporated to form CX, the malonate moiety can be deprotected and decarboxylated to provide the target compound CXI. In some cases the ketone moiety of intermediate CHI may need to be protected to avoid undesired side reactions. If required, protection as an acetal using the protocols like those described in Hwu. et al.. J. Org. Chem. 50, 3946 (1 85), is generally preferred,
o M 1 . . COCl,2 t o M , 1 ) T LMHMSCD1 S o II
R ^-0H 2) CH,N, R ^/ X 2) NBS R ^CH, ci 3) rø cm en
0 0
Y-X
NaH. THF PO OP Nafi THF PO AA OP
CV crv
General Method B - The compounds of this invention in which two R6gr°ιιps are joined to form a substituted 5-member ring E are most conveniently prepared by method B. In this method acid MI (R=H) is prepared using the protocols described in Beeley, et al., Tetrahedron 37 Suppl., 411 (1981 ). The acid is protected as an ester [e.g., R= benzyl (Bn) or 2-(trimethylsiiyl)ethyl (TMSE)] by use of coupling agents such as l-(3-dimnethylaminopropyl-3-ethylcarbodiimide) hydrochloride and procedures well known to those skilled in the art. The Grignard reagent Mil [prepared from the
corresponding bromide by treatment with magnesium] is reacted with MI (R = Bn, TMSE) to yield alcohol MOI. Alcohol MIH is eliminated via base treatment of its mesylate using conditions well known to those skilled in the art to yield olefin MTV Ozonolysis of MTV (workup with methvsulfide) yields aldehyde MV Alternatively, treatment with OsO4 followed by H<106 converts MIV to MV
Conversion of key intermediate MV to the targeted patent compounds is accomplished in several ways depending on the identity of side chain function J Reaction of MV with Wittig reagents followed by hydrogenation yields products in which J is alkyl, aryl or arylalky 1 Selective reduction of aldehyde MV with a reducing agent such as lithium tπs[(3-ethyl-3-penryl)oxy]alumιnum hydπde (LTEPA) yields alcohol MVI The alcohol may be converted to phenyl ethers or a vaπety of heteroatom substituted deπvatives used to generate sidechain R16 via the Mitsunobu reaction The Mitsunobu reaction is well known to those skilled in the art, see Mitsunobu. Synthesis 1 (1981), and Hughes, Organic Reactions-, 42, 335 (1992) Alternatively alcohol MVI is converted to a leaving group such as tosylate MVII or bromide by conditions well known to those skilled in the art and then the leaving group is displaced by the appropπate nucleophile Several examples of this type of reaction can be found in Norman, et al , Med Chem 37, 2552 (1994) Direct acylation of the alcohol MVI yields compounds in which J = OAcyl and reaction of the alcohol with vanous alkyl halides in the presence of base yields alkyl ethers In each case a final step is removal of acid blocking group R to yield acids (R = H) by using conditions which depend on the stability of R and J, but in all cases well known to those skilled in the art Removal of the benzyl group, for example, may be accomplished by base hydrolysis or hydrogenolysis, whereas deprotection of the 2-(tnmethylsιlyl)ethyl ester is typically earned out by simple treatment with tetrabutylammonium fluoride
Suitable pharmaceutical K acceptable salts of the compounds of the present
include addition salts formed with organic or inorganic bases The salt forming ion deπved from such bases can be metal ions, e g , aluminum, alkali metal ions, such as sodium or potassium, alkaline earth metal ions such as calcium or magnesium, or an amine salt ion. of which a number are known for this purpose Examples include ammonium salts, arylalkvlamines such as dibenzylamine and \ \-dibenzylethyienediamine. lower alkylamines such as methylamine, .-butylamine, procaine. lower aikylpipeπdines such as Λ-ethylpipeπdine cycloalkvlamines such as cyclohexylamine or dιc\ciohexylarrune. 1 -adamantylamιne. benzathme. or salts deπved from amino acids like arginine. lvsine or the like The physiologically acceptable salts such as the sodium or potassium salts and the ammo acid salts can be used medicinally as descπbed below and are preferred These and oU er salts which are not necessaπly physiologically acceptable are useful in isolating or puπfying a product acceptable for the purposes descπbed below For example, the use of commercially available enantiomeπcally pure amines such as (-t-)-cιnchonme in suitable solvents can yield salt crystals of a single enatiomer of the invention compounds, leaving the opposite enantiomer in solution in a process often referred to as "classical resolution " As one enantiomer
of a given mvention compound is usually substantially greater in physiological effect than its antipode. this active isomer can thus be found puπfied in either the crystals or the liquid phase. The salts are produced by reacting the acid form of the invention compound with an equivalent of the base supplying the desired basic ion in a medium in which the salt precipitates or in aqueous medium and then lyophilizing. The free acid form can be obtained from the salt by conventional neutralization techniques, e.g.. with potassium bisulfate. hydrochioπc acid. etc.
The compounds of the present invention have been found to inhibit the matnx metalloproteases MMP-3. MMP-9 and MMP-2. and to a lesser extent MMP-1 , and are therefore useful for treating or preventing the conditions referred to in the background section. As other MMPs not listed above share a high degree of homology with those listed above, especially in the catalytic site, it is deemed that compounds of the invention should also inhibit such other MMPs to varying degrees. Varying the substituents on the biaryl portions of the molecules, as well as those of the propanoic or butanoic acid chains of the claimed compounds, has been demonstrated to affect the relative inhibition of the listed MMPs. Thus compounds of this general class can be "tuned" by selecting specific substituents such that inhibition of specific MMP(s) associated with specific pathological conditions can be enhanced while leaving non-involved MMPs less affected.
The method of treating matnx metal loprotease-mediated conditions may be practiced in mammals, including humans, which exhibit such conditions.
The inhibitors of the present invention are contemplated for use in veteπnary and human applications. For such purposes, they will be employed in pharmaceutical compositions containing active mgredιent(s) plus one or more pharmaceutically acceptable carriers, diluents, fillers, binders, and other excipients, depending on the administration mode and dosage form contemplated.
Administration of the inhibitors may be by any suitable mode known to those skilled in the art. Examples of suitable parenteral administration include intravenous, intraarticular, subcutaneous
and intramuscular routes. Intravenous administration can be used to obtain acute regulation of peak plasma concentrations of the drug Improved half-life and targeting of the drug to the joint cavities may be aided by entrapment of the drug in liposomes. It may be possible to improve the selectivity of posomal targeting to the joint cavities by incorporation of ligands into the outside of the liposomes that bind to synovial-specific macromolecules Alternatively intramuscular, intraarticular or subcutaneous depot injection with or without encapsulation of the drug into degradable microspheres e g . compπsing poly(DL-lactιde-co-glycolιde) may be used to obtain prolonged sustained drug release For improved convenience of the dosage form it may be possible to use an l p implanted reservoir and septum such as the Percuseal system available from Pharmacia Improv ed convenience and patient compliance may also be achieved by the use ot either injector pens (e g the Novo Pin or Q-pen) or needle -free jet injectors (e g from Bioject. Mediject or Becton Dickinson) Prolonged zero-order or other precisely controlled release such as pulsatile release can also be achieved as needed using implantable pumps with delivery of the drug through a cannula into the synovial spaces Examples include the subcutaneously implanted osmotic pumps available from ALZA. such as the ALZET osmotic pump
Nasal delivery may be achieved by incorporation of the drug into bioadhesive paniculate earners ( 200 um) such as those compnsing cellulose, polvacrvlate or polycarbophil. in conjunction with suitable absorption enhancers such as phospholipids or acylcamitines Available systems include those developed by DanBiosys and Scios Nova
A noteworthy attπbute of the compounds of the present invention in contrast to those of various peptidic compounds referenced m the background section of this application is the demonstrated oral activity of the present compounds Certain compounds have shown oral bioavailabihty in vanous animal models of up to 90 - 98 % Oral delivery may be achieved by incorporation of the drug into tablets, coated tablets, dragees. hard and soft gelatine capsules,
solutions, emulsions or suspensions. Oral delivery may also be achieved by incorporation of the drug into enteric coated capsuies designed to release the drug into the colon where digestive protease activity is low Examples include the OROS-CT'Osmet™ and PULSINCAP™ systems from ALZA and Scherer Drug Delivery Systems respectively. Other systems use azo-crosslinked polymers that are degraded by colon specific bacterial azoreductases, or pH sensitive polyacrylate polymers that are activated by the rise in pH at the colon The above systems may be used in com unction with a wide range of available absorption enhancers.
Rectal delivery may be achieved by incorporation of the drug into suppositoπes.
The compounds of this invention can be manufactured into the above listed formulations by the addition of vanous therapeutically inert, inorganic or organic earners well known to those skilled in the art. Examples of these include, but are not limited to, lactose, com starch or derivatives thereof, talc, vegetable oils, waxes, fats, polyols such as polyethylene glycol. water, saccharose, alcohois. glyceπn and the like. Vanous preservatives, emulsifiers. dispersants. flavorants. wetting agents, antioxidants. sweeteners, colorants, stabilizers, salts, buffers and the like are also added, as required to assist in the stabilization of the formulation or to assist in increasing bioavailabihty of the active ιngredιent(s) or to yield a formulation of acceptable flavor or odor in the case of oral dosing.
The amount of the pharmaceutical composition to be employed will depend on the recipient and the condition being treated The requisite amount may be determined without undue experimentation by protocols known to those skilled in the art. Alternatively, the requisite amount may be calculated, based on a determination of the amount of target enzyme which must be inhibited in order to treat the condition.
The matrix metalloprotease inhibitors of the invention are useful not only for treatment of the physiological conditions discussed above, but are also useful in such activities as purification
of metalloproteases and testing for matnx metalloprotease activity Such activity testing can be both m vitro using natural or synthetic enzyme preparations or in vivo using, for example, animal models in which abnormal destructive enzyme levels are found spontaneously (use of genetically mutated or transgenic ammals) or are induced by admimstration of exogenous agents or by surgery which disrupts joint stability
The following examples are offered for illustrative purposes only and are not intended, nor should they be construed, to limit the invention in any way
EXAMPLES General Procedures:
All reactions were performed in flame-dπed or oven-dned glassware under a positive pressure of argon and were stirred magnetically unless otherwise indicated Sensitive liquids and solutions were transferred via synnge or cannula and were introduced into reaction vessels through rubber septa Reaction product solutions were concentrated using a Buchi evaporator unless otherwise indicated.
Materials:
Commercial grade reagents and solvents were used without further puπfication except that diethyl ether and tetrahydrofuran were usually distilled under argon from benzophenone ketyl. and methylene chloride was distilled under argon from calcium hydπde. Many of the specialty organic or organometallic starting mateπals and reagents were obtained from Aldπch, 1001 West Saint Paul
Avenue, Milwaukee, WI 53233 Solvents are often obtained from EM Science as distributed by VWR Scientific.
Chromatography:
Analytical thin-layer chromatography (TLC) was performed on Whatman* pre-coated glass-backed sihca gel 60 A F-254 250 um plates. Visualization of spots was effected by one of the following techmques: (a) ultraviolet illumination, (b) exposure to iodine vapor, (c) immersion of the plate in a 10% solution of phosphomolybdic acid in ethanol followed by heating, and (d) immersion of the plate in a 3% solution of p-arusaidehyde in ethanol containing 0.5% concentrated suifuπc acid followed by heating.
Column chromatography was performed using 230-400 mesh EM Science* silica gel .Analytical h gh performance liquid chromatography (HPLC) was performed at 1 mL min ' on a 4 6 \ 250 mm Microsorb* column monitored at 288 nm. and semi-preparative HPLC was performed at 24 mL mm'1 on a 21 4 x 250 mm Microsorb* column monitored at 288 nm. Instrumentation:
Melting points (mp) were determined with a Thomas-Hoover melting point apparatus and are uncorrected. Proton (Η) nuclear magnetic resonance (NMR) spectra were measured with a General
Electπc GN-OMEGA 300 (300 MHz) spectrometer, and carbon thirteen ( | JC) NMR spectra were measured with a General Electπc GN-OMEGA 300 (75 MHz) spectrometer. Most of the compounds synthesized m the expeπments below were analyzed by nmr. and the spectra were consistent with the proposed structures in each case Mass spectral (MS) data were obtained on a jatos Concept 1 -H spectrometer by hquid-cesium secondary ion (LCIMS), an updated version of fast atom bombardment (FAB). Most of the compounds synthesized in the experiments below were analyzed by mass spectroscopy, and the spectra were consistent with the proposed structures in each case.
General Comments:
For multi-step procedures, sequential steps are noted by numbers
EXAMPLES 1 - 6 - Preparation of Compounds I- VI Step 1 A solution of sodium hydnde (4.35 g, 1 81 mmol) in freshly distilled THF (100 mL) was cooled to 0 °C and treated with commercially available dially malonate (35 0 g, 190 mmol ) over 40 min via a dropping funnel After stirnng at room temperature for 30 min. Λ'-(2- bromoethyOphthahmide (43 9 g, 247 mmol) was added to the solution in one portion and the mixture was heated at reflux After 48 h the solution was cooled to 0°C, quenched with 2N HCI and concentrated to about 20% of its oπginal volume The concentrate was diluted with ethyl acetate (300 mL) and washed successively with saturated aqueous solutions of K CO-, and NaC l The organic layer was dned over MgSO4, filtered and concentrated under reduced pressure Puπfication by flash column chromatography (gradient eiution with 5-25% ethyl acetate-hexanes) provided diallyi 2-phthalιmιdoethylmalonate (451.2 g. 64%) as a colorless oil 'H NMR (300 MHZ, CDC1 ,) δ 7 82 (m. 2H). 7 72 (m. 2H). 5 85 (m. 2H). 5 30 (m. 2H). 5 22 (m, 2H). 4 60 (m. 4H). 3 80 (t. J = 6 6 Hz. 2H). 346 (t. = 7 2 Hz. 1H). 2 30 (dd. J = 13 8. 6 9 Hz. 2H) The product of the above- descπbed reaction is illustrated below
Step 2 A one-necked, 50-mL, round-bottomed flask equipped with a rubber septum and an argon needle inlet was charged with 12 mL THF. tπmethylsilyl chloπde (0 83 ml. 0 710 g, 6.54
mmol). lithium hexamethyldisilazide (6.50 ml. 1.0 M in THF, 6.50 mmol), and cooled to -78 °C while a solution of 2-dodecanone (1.19 g. 6.46 mmol) in 8.0 ml THF was added dropwise over a period of 30 mm via cannula. The resulting mixture was stirred at -78 °C for 30 min. Λ- bromosuccinimide (1.27 g. 7.13 mmol) was added, and the reaction mixture was stirred at -78 °C for 30 min. diluted with 200 ml of pentane. and washed with three 50 mL portions of bπne. The organic phase was dried over Na}SO4 and concentrated to provide 2.5 g of a yellow solid Column chromatography on 100 g of silica gel (gradient elution with 3-5% ethyl acetate-hexanes) afforded 0.680 g (40%) of the bromomethyl ketone as a white solid. TLC (5% ethyl acetate-hexanes) R7=0 4 The product of the above-descπbed reaction is illustrated below:
O
Step 3. A one-necked. 25 -mi. round-bottomed flask equipped with a rubber septum and an argon needle inlet was charged with 3 ml of THF and the product of step 1 (314 mg. 0.978 mmol). The resulting mixture was cooled to 0 °C and sodium t-butoxide (88.0 mg, 97% pure. 0.888 mmol) was added. .After 30 mm. a solution of the product of step 2 (250 mg, 0.950 mmol) in 3 ml of THF was added dropwise via synnge. The resulting mixture was allowed to warm to room temperature and stirred for 16 h. The reaction mixture was diluted with 100 ml of CH2C1: and washed with three 30 ml portions of brine. The organic layer was dned over MgSO4 and concentrated. Column chromatography on 40 g silica gel (gradient elution with 10-30% ethyl acetate-hexanes) afforded 0.300 g (63%) of the desired product as a white solid. TLC (30% ethyl acetate-hexanes) Rf=0.5.
The product of the above-described reaction is illustrated below:
Step 4 Preparation of Example 1. A one-necked. 154-mL. round-bottomed flask equipped with a rubber septum and an argon needle inlet was charged with 2 mL of dioxane. the product of step 3 ( 300 mg. 0.556 mmol). pyrrolidine (0.12 ml, 0.102 g, 1 44 mmol). and tetrakιs(mphenylphospιne)palladιum ( 10.0 mg. 0.0086 mmol). The resulting mixture was exposed to a slight vacuum to degas the solution and argon was reintroduced. The reaction mixture was stirred at room temperature for 12 h. the dioxane and pyrrolidine were removed in vacuo. and the residue was redissolved in 2 ml dioxane. The resulting mixture was exposed to a slight vacuum to degas the solution and argon was reintroduced. The reaction mixture was heated at 1 15 CC for 4 h. 85 °C for 12 h. and concentrated. Column chromatography on 10 g of silica gel (30% ethyl acetate- hexanes with 0.5% acetic acid) afforded 0.137 g (59%) of Example 1 as a white solid (MP 89- 90°C). The product of d e above-descπbed reaction is illustrated below:
The above methods for the preparation of Example 1 were used to prepare the following examples (TABLE I) using the appropriate bromoketones in step 3.
TABLE I
'Preparation of 1 -bromo-2-tetradecanone A one-necked. 100-mL. round-bottomed flask equipped with a rubber septum and an argon needle inlet was charged with 16 mL CC 14. 1.2-epoxιtetradecane (2 0 mL. 1 66 g, 7 82 mmol), polyvinyl pyndine (1 00 g), and bromine (0.20 ml, 0.62 g, 3 88 mmol) The resulting mixture was stirred at room temperature under irradiation of a desk lamp (soft white, 60 W) for 30 mm. The reacuon mixture was diluted with a 1 1 mixture of hexane:ethyl acetate (150 ml), washed with a 50 mL portion of saturated NaHCOv and washed with a 50 mL portion of bπne The organic layer was dned over MgSO„ and concentrated Column chromatography on 100 g of silica gel (gradient eluϋon with 5-10% ethyl acetate-hexanes) afforded 0 440 g (39%) of 1 -bromo-2- tetradecanone as a white solid TLC (5% ethyl acetate-hexanes) R, = 0.4
EXAMPLES 7 ■ 9 - Preparation of Compounds VTI-IX
Step 1. A solution of 4-(4-methoxyphenyl)-butyπc acid (3 04 g, 15 4 mmol) in CH,C1 , (45 mL) was treated with oxalyl chlonde (1 1 6 mL, 2.0 M soln. in dichloromethane) and DMF ( 1 drop) The solution was heated to reflux for 2 h. cooled to 0°C and treated with an excess of diazomethane
(ether soln.). After stiirmg an additional 30 mm. excess 4 M HCI (soln. in 1.4-dιoxane) was added and the mixture was warmed to room temperature and stirred ovemite The solution was concentrated under reduced pressure, diluted with ethyl acetate and successively washed with water, satd. aq NaHCO3 and satd. aq. NaCl The organic phase was dned over MgSO filtered and concentrated. Purification by MPLC (5-25% EtOAc-hexanes) provided the target compound (2 45 g. 70%) as a colorless oil. TLC R/ 0 45 (silica, 15% ethyl actate-hexane). The resulting compound is illustrated below:
Step 2. A solunon of sodium hydnde (6 35 g. 264 mmol) in THF (500 mL) was treated with diethyl malonate (47.35 mL, 312 mmol) After stirnng for 2 h. (2-bromoethyl)benzene (32.8 mL, 240 mmol) was carefully added to the reaction mixture. Following the addition, the solution was heated to a gentle reflux for 16 h. cooled to 0°C and quenched with 2 N HCI . The resulting solution was concentrated under reduced pressure, diluted widi EtOAc and washed with satd. aq. NaCl . The organic layer was dried over N!.:SO4 and concentrated. Vacuum distillation ( 1 5 mm Hg) provided the substituted malonate (444 g. 71%) as a colorless oil TLC. R/ 0 52 (silica, 20% ethyl actate- hexane). The resulting compound is illustrated below
Step 3. A solution of malonate from step 2 (3.50 g, 13.2 mmol) in DME (5 mL) was treated with NaOEt (0.67 g, 9.9 mmol) and stirred for 30 mm. While the solution was stimng, a separate flask containing a solution of the α-chloro ketone from step 1 (0.95 g, 4.2 mmol) in DME (5 mL) was treated witii Lil (0.62 g, 4.6 mmol), stirred for 15 min. and cannulated into the first solution. After stimng ovemite, the reaction mixture was diluted with EtOAc and washed with water and
satd aq NaCl The orgamc layer was dned over MgSO4, filtered and concentrated Puπfication by MPLC (5-20% EtOAc- hexanes) provided the desired malonate (0 41 g. 21 %) as a colorless oil TLC R/ 0 30 (silica, 20% ethyl actate-hexane) The resulting compound is illustrated below
Step 4 - Preparation of Example 7. A solution of the diester from step 3 (0 19 g, 0 42 mmol) in ethanol (3 mL) was treated with 2 N NaOH (0.5 mL) and stirred at room temperature After stimng for 16 h. the soln was concentrated under reduced pressure, diluted with ethyl acetate, and washed with aq K.:CO The aqueous layer was acidified to pH 1 with 2 N HCI . and extracted with ethyl acetate The orgamc layer was dned over MgSO4. filtered and concentrated The resulting diacid was dissolved in 1 ,4-dιoxane (3 mL) and heated to 65 °C After stimng for 24 h, the soln was concentrated and puπfied by flash column chromatography (2-4% MeOH-CH2Cl 2) to give the targeted compound (72 1 mg. 49%) MP 70-71 °C The resulting compound (Example 7) is illustrated below
The above methods for the preparation of Example VU were used to prepare the following examples (Table U)
TABLE π
EXAMPLE 10 Biological Assays of Invention Compounds P218 Quenched Fluorescence Assav for MMP Inhibition:
The P218 quenched fluorescence assay ( icrofluorometπc Profiling Assay) is a modification of that oπgmally descπbed by Kmght, et al . FEBS Lett. 296. 263, 1992 for a related substance and a vaπety of matnx metalloproteinases (MMPs) in cuvettes The assay was run with each invenuon compound and the three MMPs. MMP-3. MMP-9 and MMP-2. analyzed in parallel, adapted as follows for a 96-well microtiter plate and a Hamilton AT* workstation.
P218 Fluorogenic Substrate:
P218 is a synthetic substrate containing a 4-acetyl-7-methoxycoumaπn ( MCA) group in the N-terminal position and a 3-[2, 4-dιnιtrophenyl]-L-2,3-dιamιnopropionyl (DPA) group internally. This is a modification of a peptide reported by Knight ( 1992) that was used as a substrate for matnx
metalloproteinases. Once the P218 peptide is cleaved (putative clip site at the Ala-Leu bond), the fluorescence of the MCA group can be detected on a fluorometer with excitation at 328 nm and emission at 393 nm. P218 is currently being produced BACHEM exclusively for Bayer. P218 has the structure: H-MCA-Pro-Lys-Pro-Leu- _/α-Zeu-DPA-Ala-Arg-NH2 (MW 1332.2)
Recombinant Human CHO Stromelvsin (MMP-3)
Recombinant Human CHO Pro-MMP-3: Human CHO pro-stromelysιn-257 (pro-MMP-3) was expressed and purified as descπbed by Housley, et al., J. Biol. Chem. 268. 4481 (1993)
Activation of Pro-MMP-3 : Pro-MMP-3 at 1.72 μM (100 μg/mL) in 5 mM Tris at pH 7.5. 5 M CaCl:. 25 mM NaCl. and 0 005% Brij-35 MMP-3) activation buffer) was activated by incubation with TPCK (N-tosyl-(L)-phenylalanine chloromethyl ketone) trypsin (1 : 100 w/w to pro- MMP-3) at 25 °C for 30 min. The reaction was stopped by addition of soybean trypsin inhibitor (SBTI; 5 : 1 w/w to trypsin concentration). This activation protocol results in the formation of 45 kDa active MMP -3. which still contains the C-terminal portion of the enzyme. Preparation of Human Recombinant Pro-Gelatinase A fMMP-2):
Recombinant Human Pro-MMP-2: Human pro-gelatinase A (pro-MMP-2) was prepared using a vaccinia expression system according to the method of Fridman. et ai.. J. Biol. Chem. 267. 15398 (1992).
Activation of Pro-MMP-2. Pro-MMP-2 at 252 mg'mL was diluted 1 :5 to a final concentration of 50 μg/mL solution in 25 mM Tris at pH 7.5, 5 mM CaCl,, 150 mM NaCl, and
0.005%o Brij-35 (MMP-2 activation buffer). /7-Ammophenylmercuric acetate (APMA) was prepared in 10 mM (3.5 mg/mL) in 0.05 NaOH. The APMA solution was added at 1/20 die reaction volume for a final AMPA concentration of 0.5 mM, and die enzyme was incubated at 37 °C for 30 min. Activated MMP-2 (15 mL) was dialyzed twice vs. 2 L of MMP-2 activation buffer (dialysis
membranes were pre-treated with a solution consisting of 0.1% BSA in MMP-2 activation buffer for 1 min, followed by extensive H:O washing). The enzyme was concentrated on Centricon concentrators (concentrators were also pre-treated with a solution consisting of 0.1 % BSA in MMP- 2 activation buffer for 1 min.. followed by washing with H:0, then MMP-2 activation buffer) with re-dilution followed by re-concentration repeated twice. The enzyme was diluted to 7.5 mL (0.5 times the oπginal volume) with MMP-2 activation buffer. Preparation of Human Recombinant Pro-Gelatinase B (MMP-9):
Recombinant Human Pro-MMP-9: Human pro-gelatinase B (pro-MMP-9) derived from U937 cDNA as described by Wilhelm, et al. J. Biol. Chem. 264, 17213 (1989) was expressed as the full-length form using a baculovirus protein expression system. The pro-enzyme was purified using methods previously described by Hibbs. et al. J. Biol. Chem. 260, 2493 (1984).
Activation of Pro- MMP -9: Pro-MMP-2 20 μg/mL in 50 mM Tris at pH 7.4, lOmM CaCl2. 150 mM NaCl, and 0.005% Brij-35 ( MP-9 activation buffer) was activated by incubation with 0.5 mM
acetate (APMA) for 3.5 h at 37 °C. The enzyme was dialyzed against the same buffer to revmove the APMA.
Instrumentation:
Hamiltion Microlab AT Plus: The MMP-Profiling Assay is performed robotically on a Hamilton MicroLab AT Plus*. The Hamilton is programmed to: ( 1 ) serially dilute up to 1 1 potential inhibitors automatically from a 2.5 mM stock in 100% DMSO; (2) distribute substrate followed by inhibitor into a 96 well Cytofluor plate; and (3) add a single enzyme to the plate with mixing to start the reaction. Subsequent plates for each additional enzyme are prepared automatically by beginning the program at the substrate addition point, remixing the diluted inhibitors and beginning the reaction by addition of enzyme. In this way, all MMP assays were done using die same inhibitor dilutions.
Milhpore Cytofluor II Following incubation, the plate was read on a Cytofluor II fluorometnc plate reader wi excitation at 340 nM and emission at 395 nM with the ga set at 80 Buffers:
Microfluoromemc Reaction Buffer (MRB): Dilution of test compounds, enzymes, and P218 substrate for the microfluorometπc assay were made in microfluorometπc reaction buffer consisting of 50 mM 2-(N-morpholιno)ethanesulfonιc acid (MES) at pH 6.5 widi 10 mM CaCl2, 150 mM NaCl. 0.005% Brij-35 and 1 % DMSO Methods:
MMP Microfluoromemc Profiling Assay The assay is done with a final substrate concentration of 6 uM P218 and approximately 5 to 8 nM MMP with vanable drug concentrations.
The Hamilton is programmed to senally dilute up to 1 1 compounds from a 2.5 mM stock (100% DMSO) to l Ox the final compounds concentrations in the assay Initially, the instrument delivers various amounts of microfluoromentnc reaction buffer (MRB) to a 96 tube rack of 1 ml Marsh dilution tubes. The instrument then picks up 20 μl of inhibitor (2.5 mM) from the sample rack and mixes it with a buffer in row A of the Marsh rack, resulting m a 50 μM drug concentration. The inhibitors are then serially diluted to 10. 5, 1 , 2. .05 and 01 μM. Position 1 on die sample rack contains only DMSO for the "enzyme-only" wells in the assay, which results in no inhibitor in column 1, rows A through H. The instrument then distπbutes 107 μl of P218 substrate (8.2 μM in MRB) to a single 96 well cytofluor microtiter plate. The instrument re-mixes and loads 14.5 μl of diluted compound from rows A to G in the Marsh rack to corresponding rows in die microtiter plate.
(Row H represents the "background" row and 39.5 μl of MRB is delivered in placed of drug or enzyme). The reaction is started by adding 25 μl of die appropπate enzyme (at 5.86 times the final enzyme concentration) from a BSA treated reagent reservoir to each well, excluding Row H, d e "background" row. (The enzyme reservoir is pretreated with 1% BSA in 50 mM Tris, pH 7.5
containmg 150 mM NaCl for 1 hour at room temp., followed by extensive H O washing and drying at room temp.).
After addition and mixing of the enzyme, the plate is covered and incubated for 25 mm. at 37 °C. Add onal enzymes are tested in the same manner by beginning the Hamilton program with the distnbution of P218 substrate to the microtiter plate, followed by re-mixing and distπbution of the drug from the same Marsh rack to the microtiter plate. The second (or third, etc.) MMP to be tested is then distributed from a reagent rack to the microtiter plate with mixing, pπor to coveπng and incubation This is repeated for all additional MMP's to be tested.
IC50 Determination in Microfluoromemc Assay Data generated on the Cytofluor II is copied from an exported ".CSV" file to a master Excel spreadsheet. Data from several different
MMPs (one 96 well plate per MMP) were calculated simultaneously. The percent inhibition is determination for each drug concentration by compaπng the amount of hydrolysis (fluorescence units generated over 25 minutes of hydrolysis) of wells containing compound widi the "enzyme only" wells in column 1 Following subtraction of the background the percent inhibition was calculated as:
((Control values - Treated values)/Control values) x 100 Percent inhibitions were determined for inhibitor concentrations of 5, 1, 0 5. 0.1. 0.02,0 .005 and, 0.001 μM of drug. Linear regression analysis of percnet inhibition versus log inhibitor concentration was used to obtain IC50 values. Profiling Assay Data for Invention Compounds.
All IC50 values are expressed as nM. When "I = x %" is shown, x represents the % inhibition at 5 μM.
Table III
Other embodiments of the invention will be apparent to those skilled in the art from a consideration of this specification or practice of the invention disclosed herein It is intended that the specification and examples be considered as exemplary only, with the true scope and spiπt of the invention being indicated by the following claims
Claims
We claim:
1 A matrix metalloproteinase-inhibiting compound having die generalized formula.
wherem y is 0, 2, or, 3, r is 0-6. Z is (CH2)7 or (CH2)e-C6H4-(CH2)f, wherem e is 0-1 and f is 1 -6; R15
wherein n is 0-4, R" is C2H5, allyl. benzyl, and R16 is
wherem t is 0-1, x is 0-4, and R4 is one of the following: halide. alkyl of 1-6 carbons, OR, NR2, NO, (R = H or alkyl of 1-6 carbons).
2. A method of inhibiting matnx metalloprotease activity compπsing providing an effective matnx metalloprotease-inhibiting amount of a compound according to ciaim 1.
3 A matnx metalloprotease inhibiting composiuon compπsing a compound according to claim 1 and a pharmaceutically acceptable carrier.
4. A method of treating a mammal comprising administenng to the mammal a matnx metalloprotease inhibiting amount of a compound according to claim 1 sufficient to:
(a) alleviate the effects of osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, comeal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa. conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, demyelating diseases of the nervous system;
(b) retard tumor metastasis or degenerative cartilage loss following traumatic joint injury;
(c) reduce coronary thrombosis from athrosclerotic plaque rupture; or (d) effect birth control.
5. The method of claim 4 wherein said mammal is a human.
6. The method of claim 4 wherein the effect is alleviation of osteoarthritis.
7. The method of claim 4 wherein the effect is retardation of tumor metastasis.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97926454A EP0912487A1 (en) | 1996-05-15 | 1997-05-12 | Substituted oxobutyric acids as matrix metalloprotease inhibitors |
AU31219/97A AU727648B2 (en) | 1996-05-15 | 1997-05-12 | Substituted oxobutyric acids as matrix metalloproteinase inhibitors |
BR9708998A BR9708998A (en) | 1996-05-15 | 1997-05-12 | Matrix metalloproteinase inhibition compound processes to inhibit matrix metalloprotease activity and to treat a mammal and matrix metalloprotease inhibition composition |
JP54100297A JP3417951B2 (en) | 1996-05-15 | 1997-05-12 | Substituted oxybutyric acids as matrix metalloprotease inhibitors |
CA002253869A CA2253869C (en) | 1996-05-15 | 1997-05-12 | Substituted oxobutyric acids as matrix metalloprotease inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64838496A | 1996-05-15 | 1996-05-15 | |
US08/648,384 | 1996-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997043238A1 WO1997043238A1 (en) | 1997-11-20 |
WO1997043238A9 true WO1997043238A9 (en) | 1998-03-05 |
Family
ID=24600568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/007975 WO1997043238A1 (en) | 1996-05-15 | 1997-05-12 | Substituted oxobutyric acids as matrix metalloprotease inhibitors |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0912487A1 (en) |
JP (1) | JP3417951B2 (en) |
CN (1) | CN1163466C (en) |
AR (1) | AR007096A1 (en) |
AU (1) | AU727648B2 (en) |
CA (1) | CA2253869C (en) |
CO (1) | CO4990925A1 (en) |
HR (1) | HRP970246B1 (en) |
ID (1) | ID20291A (en) |
MY (1) | MY132470A (en) |
PA (1) | PA8429401A1 (en) |
PE (1) | PE65998A1 (en) |
SV (1) | SV1997000034A (en) |
TN (1) | TNSN97085A1 (en) |
TW (1) | TW467892B (en) |
WO (1) | WO1997043238A1 (en) |
YU (1) | YU18797A (en) |
ZA (1) | ZA974032B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
JP5263548B2 (en) * | 2007-08-15 | 2013-08-14 | 杏林製薬株式会社 | A preventive, suppressive or therapeutic agent for cerebral aneurysms containing ibudilast as an active ingredient |
EP3126339A1 (en) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids and use thereof |
EP3126358A1 (en) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases |
CA2944617A1 (en) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3827324B2 (en) * | 1994-01-22 | 2006-09-27 | ブリテッシュ バイオテック ファーマシューティカルズ リミテッド | Metalloproteinase inhibitor |
-
1997
- 1997-05-09 HR HR970246A patent/HRP970246B1/en not_active IP Right Cessation
- 1997-05-09 MY MYPI97002045A patent/MY132470A/en unknown
- 1997-05-09 ZA ZA9704032A patent/ZA974032B/en unknown
- 1997-05-09 TN TNTNSN97085A patent/TNSN97085A1/en unknown
- 1997-05-09 CO CO97025164A patent/CO4990925A1/en unknown
- 1997-05-12 AR ARP970101976A patent/AR007096A1/en unknown
- 1997-05-12 AU AU31219/97A patent/AU727648B2/en not_active Ceased
- 1997-05-12 PA PA19978429401A patent/PA8429401A1/en unknown
- 1997-05-12 CN CNB971964599A patent/CN1163466C/en not_active Expired - Fee Related
- 1997-05-12 CA CA002253869A patent/CA2253869C/en not_active Expired - Fee Related
- 1997-05-12 EP EP97926454A patent/EP0912487A1/en not_active Withdrawn
- 1997-05-12 TW TW086106284A patent/TW467892B/en not_active IP Right Cessation
- 1997-05-12 YU YU18797A patent/YU18797A/en unknown
- 1997-05-12 JP JP54100297A patent/JP3417951B2/en not_active Expired - Fee Related
- 1997-05-12 PE PE1997000362A patent/PE65998A1/en not_active Application Discontinuation
- 1997-05-12 SV SV1997000034A patent/SV1997000034A/en not_active Application Discontinuation
- 1997-05-12 WO PCT/US1997/007975 patent/WO1997043238A1/en not_active Application Discontinuation
- 1997-05-14 ID IDP971607A patent/ID20291A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6500847B2 (en) | Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acids | |
CA2254731C (en) | Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids | |
EP0937036B1 (en) | Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors | |
WO1997043239A9 (en) | Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids | |
US5968795A (en) | Biaryl acetylenes as inhibitors of matrix metalloproteases | |
US5863915A (en) | Substituted 4-arylbutyric acid derivatives as matrix metalloprotease | |
WO1997043238A9 (en) | Substituted oxobutyric acids as matrix metalloprotease inhibitors | |
CA2253796C (en) | Inhibition of matrix metalloproteases by acetylene containing compounds | |
AU727468B2 (en) | Subsituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors | |
AU727899B2 (en) | Inhibition of matrix metalloproteases by substituted phenalkyl compounds | |
CA2253869C (en) | Substituted oxobutyric acids as matrix metalloprotease inhibitors | |
US5932577A (en) | Substituted oxobutyric acids as matrix metalloprotease inhibitors | |
AU715877B2 (en) | Inhibition of matrix metalloproteases by 2-(omega- aroylalkyl)-4-biaryl-oxobutyric acids | |
US5804581A (en) | Inhibition of matrix metalloproteases by substituted phenalkyl compounds | |
US5932763A (en) | Inhibition of matrix metalloproteases by 2-(ω-arolalkyl)-4-biaryl-4-oxobutyric acids |